<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="01ca2f07-9bc2-e418-e063-6294a90ac760"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>Dyural 80 Kit
 <br/>
      <br/>
These highlights do not include all the information needed to use BUPIVACAINE HYDROCHLORIDE INJECTION safely and effectively. See full prescribing information for BUPIVACAINE HYDROCHLORIDE INJECTION.
 <br/>
      <br/>
BUPIVACAINE HYDROCHLORIDE injection, for infiltration, perineural, caudal, epidural, or retrobulbar use
 <br/>
      <br/>
Initial U.S. Approval: 1972
</title>
   <effectiveTime value="20230731"/>
   <setId root="01ca2f07-9c84-e418-e063-6294a90ac760"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="117023142"/>
            <name>Advanced Rx Pharmacy of Tennessee, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="117023142"/>
                        <name>Advanced Rx Pharmacy of Tennessee, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="80425-0349" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="01d0617d-dd30-9567-e063-6294a90a89e8"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20230731"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="80425-0349" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Dyural 80 Kit</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Methylprednisolone Acetate, Lidocaine Hydrochloride, Bupivacaine Hydrochloride, Povidine Iodine, Sodium Chloride, Isopropyl Alcohol</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="76420-755" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="80425-0349-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 1: Convenience Kit of Co-Package" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230731"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0409-1159" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Bupivacaine Hydrochloride</name>
                              <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>BUPIVACAINE HYDROCHLORIDE</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CHLORIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM HYDROXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROCHLORIC ACID</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIR">
                                 <quantity>
                                    <numerator unit="mg" value="2.5"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="7TQO7W3VT8" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>BUPIVACAINE HYDROCHLORIDE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="Y8335394RO" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>BUPIVACAINE</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                    <asEquivalentSubstance>
                                       <definingSubstance>
                                          <code code="AKA908P8J1" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>BUPIVACAINE HYDROCHLORIDE ANHYDROUS</name>
                                       </definingSubstance>
                                    </asEquivalentSubstance>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="mL"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0409-1159-18" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="ANDA070583" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230731"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="EPIDURAL"/>
                              </substanceAdministration>
                           </consumedIn>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INFILTRATION"/>
                              </substanceAdministration>
                           </consumedIn>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38293" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PERINEURAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="0.9" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="67777-419" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Povidine Iodine</name>
                              <formCode code="C47898" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SWAB"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Povidine Iodine</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GLYCERIN</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYSORBATE 80</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="1Q73Q2JULR" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CITRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="22ADO53M6F" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="DSO12WL7AU" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CITRIC ACID ACETATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIM">
                                 <quantity>
                                    <numerator unit="mg" value="10"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="85H0HZU99M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POVIDONE-IODINE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="9679TC07X4" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>IODINE</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="0.9" unit="mL"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="67777-419-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43199" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACKET"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="part333C" root="2.16.840.1.113883.3.149"/>
                                 <code code="C73603" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OTC monograph final"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230731"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0409-4888" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Sodium Chloride</name>
                              <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Sodium Chloride</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROCHLORIC ACID</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM HYDROXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="9"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CHLORIDE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="Q32ZN48698" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>CHLORIDE ION</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="mL"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0409-4888-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA018803" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230731"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                              </substanceAdministration>
                           </consumedIn>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="10" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="0409-4887" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Sterile Water</name>
                              <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Water</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mL" value="1"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>WATER</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="10" unit="mL"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0409-4887-17" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43214" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, PLASTIC"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA018801" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230731"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                              </substanceAdministration>
                           </consumedIn>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="25" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <name>Isopropyl Alcohol</name>
                              <formCode code="C47898" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SWAB"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Isopropyl Alcohol</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mL" value="70"/>
                                    <denominator unit="mL" value="100"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ISOPROPYL ALCOHOL</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>ISOPROPYL ALCOHOL</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="5" unit="mL"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="part333A" root="2.16.840.1.113883.3.149"/>
                                 <code code="C73604" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OTC monograph not final"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20070101"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="1" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="70121-1574" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Methylprednisolone acetate</name>
                              <formCode code="C42995" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SUSPENSION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Methylprednisolone acetate</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator unit="mg" value="28"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>POLYETHYLENE GLYCOL 3350</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3D6CWI0P23" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MIRIPIRIUM CHLORIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CHLORIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROCHLORIC ACID</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM HYDROXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator unit="mg" value="80"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="43502P7F0P" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHYLPREDNISOLONE ACETATE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="X4W7ZR7023" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>METHYLPREDNISOLONE</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="mL"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="1" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="70121-1574-1" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="ANDA210043" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230731"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                                    <originalText>white to off white</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                              </substanceAdministration>
                           </consumedIn>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38223" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRA-ARTICULAR"/>
                              </substanceAdministration>
                           </consumedIn>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38250" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRALESIONAL"/>
                              </substanceAdministration>
                           </consumedIn>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38198" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOFT TISSUE"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="55150-162" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Lidocaine Hydrochloride</name>
                              <formCode code="C42945" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Lidocaine Hydrochloride</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM CHLORIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM HYDROXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROCHLORIC ACID</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="ACTIR">
                                 <quantity>
                                    <numerator unit="mg" value="10"/>
                                    <denominator unit="mL" value="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="V13007Z41A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LIDOCAINE HYDROCHLORIDE</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="98PI200987" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>LIDOCAINE</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                    <asEquivalentSubstance>
                                       <definingSubstance>
                                          <code code="EC2CNF7XFP" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>LIDOCAINE HYDROCHLORIDE ANHYDROUS</name>
                                       </definingSubstance>
                                    </asEquivalentSubstance>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="5" unit="mL"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="10" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="55150-162-05" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                    </asContent>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="ANDA203082" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230731"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INFILTRATION"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <code code="C73627" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="unapproved drug other"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230731"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38198" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOFT TISSUE"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INFILTRATION"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38210" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="EPIDURAL"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38223" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRA-ARTICULAR"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38250" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRALESIONAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="BOX">
               <id root="01ca2f07-9bc3-e418-e063-6294a90ac760"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: RISK OF CARDIAC ARREST WITH USE OF BUPIVACAINE HYDROCHLORIDE INJECTION IN OBSTETRICAL ANESTHESIA</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">There have been reports of cardiac arrest with difficult resuscitation or death during use of Bupivacaine Hydrochloride Injection for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% (7.5 mg/mL) concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% (7.5 mg/mL) concentration of Bupivacaine Hydrochloride Injection is not recommended for obstetrical anesthesia and should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].
  
   </content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>WARNING: RISK OF CARDIAC ARREST WITH USE OF BUPIVACAINE HYDROCHLORIDE INJECTION IN OBSTETRICAL ANESTHESIA</paragraph>
                        <paragraph>
                           <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">There have been reports of cardiac arrest with difficult resuscitation or death during use of Bupivacaine Hydrochloride Injection for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% (7.5 mg/mL) concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% (7.5 mg/mL) concentration of Bupivacaine Hydrochloride Injection is not recommended for obstetrical anesthesia and should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary (
  
     <linkHtml href="#S5.1">5.1</linkHtml>).
 
    </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="01ca2f07-9bc4-e418-e063-6294a90ac760"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Bupivacaine Hydrochloride Injection is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations of Bupivacaine Hydrochloride Injection are recommended for each type of block indicated to produce local or regional anesthesia or analgesia
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>].
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Bupivacaine Hydrochloride Injection contains bupivacaine, an amide local anesthetic. Bupivacaine Hydrochloride Injection is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. For each type of block indicated to produce local or regional anesthesia or analgesia, specific concentrations and presentations are recommended. (
 
    <linkHtml href="#S1">1</linkHtml>,
 
    <linkHtml href="#S2.2">2.2</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>Not all blocks are indicated for use with Bupivacaine Hydrochloride Injection given clinically significant risks associated with use. (
 
    <linkHtml href="#S1">1</linkHtml>,
 
    <linkHtml href="#S2.2">2.2</linkHtml>,
 
    <linkHtml href="#S4">4</linkHtml>,
 
    <linkHtml href="#S5.1">5.1</linkHtml>,
 
    <linkHtml href="#S5.4">5.4</linkHtml>,
 
    <linkHtml href="#S5.5">5.5</linkHtml>,
 
    <linkHtml href="#S5.7">5.7</linkHtml>,
 
    <linkHtml href="#S5.9">5.9</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="01ca2f07-9bc5-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use</content>
                        </paragraph>
                        <paragraph>Not all blocks are indicated for use with Bupivacaine Hydrochloride Injection given clinically significant risks associated with use
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>,
  
   <linkHtml href="#S4">Contraindications (4)</linkHtml>,
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1</linkHtml>,
  
   <linkHtml href="#S5.4">5.4</linkHtml>,
  
   <linkHtml href="#S5.5">5.5</linkHtml>,
  
   <linkHtml href="#S5.7">5.7</linkHtml>,
  
   <linkHtml href="#S5.9">5.9)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="01ca2f07-9bc6-e418-e063-6294a90ac760"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20230731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Not for intrathecal use. (
  
     <linkHtml href="#S2.1">2.1</linkHtml>)
 
    </item>
                           <item>Avoid use of solutions containing antimicrobial preservatives (i.e., multiple-dose vials) for epidural or caudal anesthesia. (
  
     <linkHtml href="#S2.1">2.1</linkHtml>,
  
     <linkHtml href="#S5.4">5.4</linkHtml>)
 
    </item>
                           <item>Three mL of Bupivacaine Hydrochloride and Epinephrine Injection without antimicrobial preservative (0.5% bupivacaine with 1:200,000 epinephrine) is recommended for use as a test dose prior to caudal and lumbar epidural blocks when clinical conditions permit. (
  
     <linkHtml href="#S2.4">2.4</linkHtml>)
 
    </item>
                           <item>See full prescribing information for:
  
     <list listType="unordered">
                                 <item>Recommended concentrations and dosages of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection according to type of block. (
    
       <linkHtml href="#S2.2">2.2</linkHtml>)
   
      </item>
                                 <item>Additional dosage and administration information pertaining to use in epidural anesthesia, test dose for caudal and lumbar epidural blocks, use in dentistry, and use in ophthalmic surgery. (
    
       <linkHtml href="#S2.3">2.3</linkHtml>,
    
       <linkHtml href="#S2.4">2.4</linkHtml>,
    
       <linkHtml href="#S2.5">2.5</linkHtml>,
    
       <linkHtml href="#S2.6">2.6</linkHtml>)
   
      </item>
                              </list>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="01ca2f07-9bc7-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Dosage and Administration Information</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection is not for intrathecal use.</item>
                           <item>Avoid use of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection solutions containing antimicrobial preservatives (i.e., multiple-dose vials) for epidural or caudal anesthesia
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]
  
   </content>.
 
  </item>
                           <item>Discard unused portions of solution not containing preservatives, i.e., those supplied in single-dose vials, following initial use.</item>
                           <item>Visually inspect this product for particulate matter and discoloration prior to administration whenever solution and container permit. Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are clear, colorless solutions. Do not administer solutions which are discolored or contain particulate matter.</item>
                           <item>Mixing or the prior or intercurrent use of any other local anesthetic with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection is not recommended because of insufficient data on the clinical use of such mixtures.</item>
                        </list>
                     </text>
                     <effectiveTime value="20230731"/>
                     <component>
                        <section>
                           <id root="01ca2f07-9bc8-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Administration Precautions</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Bupivacaine Hydrochloride Injection Injection/Bupivacaine Hydrochloride and Epinephrine Injection are to be administered in carefully adjusted dosages by or under the supervision of experienced clinicians who are well versed in the diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed.</item>
                                 <item>Use Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection only if the following are immediately available: oxygen, cardiopulmonary resuscitative equipment and drugs, and the personnel resources needed for proper management of toxic reactions and related emergencies
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>,
   
    <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>,
   
    <linkHtml href="#S10">Overdosage (10)</linkHtml>]
  
   </content>.
 
  </item>
                                 <item>The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects related to local anesthetic systemic toxicity when additional local anesthetics are administered with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>,
   
    <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>,
   
    <linkHtml href="#S10">Overdosage (10)</linkHtml>]
  
   </content>.
 
  </item>
                                 <item>Aspirate for blood or cerebrospinal fluid (where applicable) prior to injecting Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection, both the initial dose and all subsequent doses, to avoid intravascular or intrathecal injection. However, a negative aspiration for blood or cerebrospinal fluid does not ensure against an intravascular or intrathecal injection
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>]
  
   </content>.
 
  </item>
                                 <item>Avoid rapid injection of a large volume of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection and use fractional (incremental) doses when feasible.</item>
                                 <item>During major regional nerve blocks, such as those of the brachial plexus or lower extremity, the patient should have an indwelling intravenous catheter to assure adequate intravenous access. The lowest dosage of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection that results in effective anesthesia should be used to avoid high plasma levels and serious adverse reactions.</item>
                                 <item>Perform careful and constant monitoring of cardiovascular and respiratory (adequacy of oxygenation and ventilation) vital signs and the patient's level of consciousness after each local anesthetic injection.</item>
                                 <item>Use Bupivacaine Hydrochloride and Epinephrine Injection in carefully restricted quantities in areas of the body supplied by end arteries or having otherwise compromised blood supply such as digits, nose, external ear, or penis
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.12">Warnings and Precautions (5.12)</linkHtml>]
  
   </content>.
 
  </item>
                              </list>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="01ca2f07-9bc9-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Concentrations and Dosages of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection</title>
                     <text>
                        <paragraph>The dosage of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection administered varies with the anesthetic procedure, the area to be anesthetized, the vascularity of the tissues, the number of neuronal segments to be blocked, the depth of anesthesia and degree of muscle relaxation required, the duration of anesthesia desired, individual tolerance, and the physical condition of the patient. Administer the smallest dosage and concentration required to produce the desired result.</paragraph>
                        <paragraph>The types of block and recommended Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection concentrations are shown in Table 1.</paragraph>
                        <table width="90%">
                           <caption>Table 1. Types of Block and Recommended Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection Concentrations</caption>
                           <col width="25%" align="left" valign="middle"/>
                           <col width="15%" align="center" valign="middle"/>
                           <col width="15%" align="center" valign="middle"/>
                           <col width="15%" align="center" valign="middle"/>
                           <col width="15%" align="center" valign="middle"/>
                           <col width="15%" align="center" valign="middle"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th rowspan="2" align="center" styleCode="Lrule Rrule">Type of Block</th>
                                 <th colspan="3" styleCode="Rrule">Bupivacaine Hydrochloride</th>
                                 <th colspan="2" styleCode="Rrule">Bupivacaine Hydrochloride and Epinephrine</th>
                              </tr>
                              <tr>
                                 <th align="center" styleCode="Rrule">0.25% 
     <br/>  (2.5 mg/mL)
    </th>
                                 <th styleCode="Rrule">0.5% 
     <br/>  (5 mg/mL)
    </th>
                                 <th styleCode="Rrule">0.75% 
     <br/>  (7.5 mg/mL)
    
     <footnote ID="K1604">Bupivacaine Hydrochloride Injection 0.75% (7.5 mg/mL) is not recommended for nonobstetrical surgical procedures in pregnant patients.</footnote>
                                 </th>
                                 <th styleCode="Rrule">0.25% 
     <br/>  (2.5 mg/mL)
    </th>
                                 <th styleCode="Rrule">0.5% 
     <br/>  (5 mg/mL)
    </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="6" align="left">✓= indicated use
    
     <content styleCode="italics">[see
     
      <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].
    
     </content>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Local infiltration</td>
                                 <td styleCode="Rrule">✓</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">✓</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Peripheral nerve block</td>
                                 <td styleCode="Rrule">✓</td>
                                 <td styleCode="Rrule">✓</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">✓</td>
                                 <td styleCode="Rrule">✓</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Retrobulbar block</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">✓</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Sympathetic block</td>
                                 <td styleCode="Rrule">✓</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Caudal block
    
     <footnote ID="tbft1">Avoid use of multiple-dose vials of Bupivacaine Hydrochloride Injection and Bupivacaine Hydrochloride and Epinephrine Injection for caudal or epidural anesthesia 
             [see 
              Warnings and Precautions (5.4)]
             .
            </footnote>
                                 </td>
                                 <td styleCode="Rrule">✓</td>
                                 <td styleCode="Rrule">✓</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">✓</td>
                                 <td styleCode="Rrule">✓</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Lumbar epidural block
    
     <footnoteRef IDREF="tbft1"/>
                                 </td>
                                 <td styleCode="Rrule">✓</td>
                                 <td styleCode="Rrule">✓</td>
                                 <td styleCode="Rrule">✓ 
     <br/>  (not for obstetrical anesthesia)
    </td>
                                 <td styleCode="Rrule">✓</td>
                                 <td styleCode="Rrule">✓</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Epidural test dose</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">✓</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Dental block</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">✓</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>At recommended dosages, Bupivacaine Hydrochloride/Bupivacaine Hydrochloride and Epinephrine produces complete sensory block, but the effect on motor function differs among the three concentrations. Table 2 provides information on the expected effect on motor function for the three concentrations.</paragraph>
                        <table width="90%">
                           <caption>Table 2. Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection Concentration vs. Motor Function</caption>
                           <col width="30%" align="left" valign="middle"/>
                           <col width="70%" align="left" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Bupivacaine Hydrochloride Injection Concentration</th>
                                 <th styleCode="Rrule">Motor Function</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">0.25% 
     <br/>  (2.5 mg/mL)
    
     <footnote ID="tb2ft1">These products include Bupivacaine Hydrochloride Injection and Bupivacaine Hydrochloride and Epinephrine Injection [the epinephrine concentration (1:200,000) is not included in the table].</footnote>
                                 </td>
                                 <td styleCode="Rrule" valign="top">When used for caudal, epidural, or peripheral nerve block, produces incomplete motor block. Should be used for operations in which muscle relaxation is not important, or when another means of providing muscle relaxation is used concurrently. Onset of action may be slower than with the 0.5% (5 mg/mL) or 0.75% (7.5 mg/mL) solutions.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">0.5% 
     <br/>  (5 mg/mL)
    
     <footnoteRef IDREF="tb2ft1"/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">Provides motor blockade for caudal, epidural, or nerve block, but muscle relaxation may be inadequate for operations in which complete muscle relaxation is essential.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">0.75% 
     <br/>  (7.5 mg/mL)
    
     <footnote ID="K1840">These are only Bupivacaine Hydrochloride Injection products [there is no 0.75% (7.5 mg/mL) concentration for Bupivacaine Hydrochloride and Epinephrine Injection].</footnote>
                                 </td>
                                 <td styleCode="Rrule" valign="top">Produces complete motor block. Most useful for epidural block in abdominal operations requiring complete muscle relaxation, and for retrobulbar anesthesia. Not for obstetrical anesthesia.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The duration of anesthesia with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection is such that for most indications, a single-dose is sufficient.</paragraph>
                        <paragraph>The maximum dosage limit within the recommended dosage range must be individualized in each case after evaluating the size and physical status of the patient, as well as the anticipated rate of systemic absorption from a particular injection site.</paragraph>
                        <paragraph>The dosages in Table 3 are recommended as a guide for use in the average adult. These doses may be repeated once every three hours. Do not exceed a total daily dosage of 400 mg in 24 hours. The duration of anesthetic effect may be prolonged by the addition of epinephrine.</paragraph>
                        <table width="90%">
                           <caption>Table 3. Recommended Concentrations and Doses of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection in Adults</caption>
                           <col width="20%" align="left" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th rowspan="2" align="center" styleCode="Lrule Rrule" valign="middle">Type of Block</th>
                                 <th rowspan="2" styleCode="Rrule" valign="middle">Concentration of Bupivacaine Hydrochloride Injection</th>
                                 <th colspan="2" styleCode="Rrule" valign="bottom">Each Dose</th>
                                 <th rowspan="2" styleCode="Rrule" valign="middle">Motor Block
    
     <footnote ID="K1900">With continuous (intermittent) techniques, repeat doses increase the degree of motor block. The first repeat dose of 0.5% (5 mg/mL) may produce complete motor block. Intercostal nerve block with 0.25% (2.5 mg/mL) also may produce complete motor block for intra-thoracic and upper intra-abdominal surgery.</footnote>
                                 </th>
                              </tr>
                              <tr>
                                 <th align="center" styleCode="Rrule" valign="middle">mL</th>
                                 <th styleCode="Rrule" valign="bottom">mg of Bupivacaine Hydrochloride Injection</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule" valign="middle">Local infiltration</td>
                                 <td rowspan="2" styleCode="Rrule">0.25% 
     <br/>  (2.5 mg/mL)
    
     <footnote ID="tb3ft1">Solutions with or without epinephrine (i.e., applies to Bupivacaine Hydrochloride Injection and Bupivacaine Hydrochloride and Epinephrine Injection). The Bupivacaine Hydrochloride and Epinephrine Injection products include epinephrine (1:200,000).</footnote>
                                 </td>
                                 <td styleCode="Rrule">Up to 70 
     <br/>  (without epinephrine)
    </td>
                                 <td styleCode="Rrule">Up to 175 
     <br/>  (without epinephrine)
    </td>
                                 <td rowspan="2" styleCode="Rrule">―</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Rrule">Up to 90 
     <br/>  (with epinephrine)
    </td>
                                 <td styleCode="Rrule">Up to 225 
     <br/>  (with epinephrine)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="4" styleCode="Lrule Rrule" valign="middle">Peripheral nerve block</td>
                                 <td rowspan="2" styleCode="Rrule">0.5% (5 mg/mL)
    
     <footnoteRef IDREF="tb3ft1"/>
                                 </td>
                                 <td styleCode="Rrule">5–35 
     <br/>  (without epinephrine)
    </td>
                                 <td styleCode="Rrule">25–175 
     <br/>  (without epinephrine)
    </td>
                                 <td rowspan="2" styleCode="Rrule">moderate to complete</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Rrule">5–45 
     <br/>  (with epinephrine)
    </td>
                                 <td styleCode="Rrule">25–225 
     <br/>  (with epinephrine)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" align="center" styleCode="Rrule">0.25% 
     <br/>  (2.5 mg/mL)
    
     <footnoteRef IDREF="tb3ft1"/>
                                 </td>
                                 <td styleCode="Rrule">5–70 
     <br/>  (without epinephrine)
    </td>
                                 <td styleCode="Rrule">12.5–175 
     <br/>  (without epinephrine)
    </td>
                                 <td rowspan="2" styleCode="Rrule">moderate to complete</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Rrule">5–90 
     <br/>  (with epinephrine)
    </td>
                                 <td styleCode="Rrule">12.5–225 
     <br/>  (with epinephrine)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Retrobulbar block 
     <br/>
                                    <content styleCode="italics">[see
     
      <linkHtml href="#S2.6">Dosage and Administration (2.6)</linkHtml>]
    
     </content>
                                 </td>
                                 <td styleCode="Rrule">0.75% 
     <br/>  (7.5 mg/mL)
    </td>
                                 <td styleCode="Rrule">2–4</td>
                                 <td styleCode="Rrule">15–30</td>
                                 <td styleCode="Rrule">complete</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Sympathetic block</td>
                                 <td styleCode="Rrule">0.25% 
     <br/>  (2.5 mg/mL)
    </td>
                                 <td styleCode="Rrule">20–50</td>
                                 <td styleCode="Rrule">50–125</td>
                                 <td styleCode="Rrule">―</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="2" styleCode="Lrule Rrule" valign="middle">Caudal block 
     <br/>
                                    <content styleCode="italics">[see
     
      <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>]
    
     </content>
                                 </td>
                                 <td styleCode="Rrule">0.5% (5 mg/mL)
    
     <footnoteRef IDREF="tb3ft1"/>
                                 </td>
                                 <td styleCode="Rrule">15–30</td>
                                 <td styleCode="Rrule">75–150</td>
                                 <td styleCode="Rrule">moderate to complete</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Rrule">0.25% 
     <br/>  (2.5 mg/mL)
    
     <footnoteRef IDREF="tb3ft1"/>
                                 </td>
                                 <td styleCode="Rrule">15–30</td>
                                 <td styleCode="Rrule">37.5–75</td>
                                 <td styleCode="Rrule">moderate</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td rowspan="3" styleCode="Lrule Rrule" valign="middle">Lumbar epidural block 
     <br/>
                                    <content styleCode="italics">[see
     
      <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]
    
     </content>
                                 </td>
                                 <td styleCode="Rrule">0.75% 
     <br/>  (7.5 mg/mL)
    
     <footnote ID="K2150">For single-dose use; not for intermittent epidural technique. Not for obstetrical anesthesia.</footnote>
                                 </td>
                                 <td styleCode="Rrule">10–20</td>
                                 <td styleCode="Rrule">75–150</td>
                                 <td styleCode="Rrule">complete</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Rrule">0.5% (5 mg/mL)
    
     <footnoteRef IDREF="tb3ft1"/>
                                 </td>
                                 <td styleCode="Rrule">10–20</td>
                                 <td styleCode="Rrule">50–100</td>
                                 <td styleCode="Rrule">moderate to complete</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Rrule">0.25% 
     <br/>  (2.5 mg/mL)
    
     <footnoteRef IDREF="tb3ft1"/>
                                 </td>
                                 <td styleCode="Rrule">10–20</td>
                                 <td styleCode="Rrule">25–50</td>
                                 <td styleCode="Rrule">partial to moderate</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Epidural test dose 
     <br/>
                                    <content styleCode="italics">[see
     
      <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>]
    
     </content>
                                 </td>
                                 <td align="center" styleCode="Rrule">0.5% (5 mg/mL) with epinephrine</td>
                                 <td styleCode="Rrule">2–3</td>
                                 <td styleCode="Rrule">10–15 
     <br/>  (10–15 micrograms epinephrine)
    </td>
                                 <td styleCode="Rrule">―</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">Dental 
     <br/>
                                    <content styleCode="italics">[see
     
      <linkHtml href="#S2.5">Dosage and Administration (2.5)</linkHtml>]
    
     </content>
                                 </td>
                                 <td align="center" styleCode="Rrule">0.5% (5 mg/mL) with epinephrine</td>
                                 <td styleCode="Rrule">1.8–3.6 per site</td>
                                 <td styleCode="Rrule">9–18 per site</td>
                                 <td styleCode="Rrule">―</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="01ca2f07-9bca-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Use in Epidural Anesthesia</title>
                     <text>
                        <paragraph>During the administration of epidural anesthesia, it is recommended that a test dose of Bupivacaine Hydrochloride and Epinephrine Injection without antimicrobial preservative (0.5% bupivacaine with 1:200,000 epinephrine) be administered initially and the effects monitored before the full dose is given. When using a "continuous" catheter technique, test doses should be given prior to both the initial and all supplemental doses, because a catheter in the epidural space can migrate into a blood vessel or through the dura
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>During epidural administration, administer Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection, 0.5% (5 mg/mL) and Bupivacaine Hydrochloride Injection 0.75% (7.5 mg/mL) solutions in incremental doses of 3 mL to 5 mL with sufficient time between doses to detect toxic manifestations of unintentional intravascular or intrathecal injection. Administer injections slowly, with frequent aspirations before and during the injection to avoid intravascular injection. Perform syringe aspirations before and during each supplemental injection in continuous (intermittent) catheter techniques. In obstetrics, use ONLY the 0.5% (5 mg/mL) and 0.25% (2.5 mg/mL) concentrations of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>];
 
  </content>incremental doses of 3 mL to 5 mL of the 0.5% (5 mg/mL) solution not exceeding 50 mg to 100 mg at any dosing interval are recommended. Repeat doses should be preceded by a test dose containing epinephrine if not clinically contraindicated. Use only the single-dose vials for caudal or epidural anesthesia; avoid use of the multiple-dose vials for these procedures, which contain a preservative
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml>,
  
   <linkHtml href="#S2.4">2.4)</linkHtml>,
  
   <linkHtml href="#S5.4">Warnings and Precautions (5.4</linkHtml>,
  
   <linkHtml href="#S5.9">5.9)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="01ca2f07-9bcb-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Test Dose for Caudal and Lumbar Epidural Blocks</title>
                     <text>
                        <paragraph>Three mL of Bupivacaine Hydrochloride and Epinephrine Injection without antimicrobial preservative (0.5% bupivacaine with 1:200,000 epinephrine) is recommended for use as a test dose prior to caudal and lumbar epidural blocks when clinical conditions permit. This test dose may serve as a warning of unintended intravascular or intrathecal injection. Closely monitor for early clinical signs of toxicity following each test dose
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>]
 
  </content>. Allot adequate time for onset of spinal block to detect possible intrathecal injection. An intravascular or intrathecal injection is still possible even if results of the test dose are negative. The test dose itself may produce a systemic toxic reaction, high spinal, or cardiovascular effects from the epinephrine
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>,
  
   <linkHtml href="#S5.9">5.9)</linkHtml>,
  
   <linkHtml href="#S10">Overdosage (10)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.5">
                     <id root="01ca2f07-9bcc-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Use in Dentistry</title>
                     <text>
                        <paragraph>Bupivacaine Hydrochloride and Epinephrine Injection 0.5% (5 mg/mL) is recommended for infiltration and block injection in the maxillary and mandibular area when a longer duration of local anesthesia is desired, such as for procedures generally associated with significant postoperative pain. The average dose of 1.8 mL (9 mg) per injection site will usually suffice; an occasional second dose of 1.8 mL (9 mg) may be used if necessary to produce adequate anesthesia after allowing 2 to 10 minutes for block onset
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>].
 
  </content>Use the lowest effective dose and allow time between injections; it is recommended that the total dose for all injection sites, spread out over a single dental sitting, not exceed 90 mg for a healthy adult patient (ten 1.8 mL injections of 0.5% (5 mg/mL) Bupivacaine Hydrochloride and Epinephrine Injection). Inject slowly and with frequent aspirations.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.6">
                     <id root="01ca2f07-9bcd-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Use in Ophthalmic Surgery</title>
                     <text>
                        <paragraph>When Bupivacaine Hydrochloride Injection 0.75% (7.5 mg/mL) is used for retrobulbar block, complete corneal anesthesia usually precedes onset of clinically acceptable external ocular muscle akinesia. Therefore, presence of akinesia rather than anesthesia alone should determine readiness of the patient for surgery
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.15">Warnings and Precautions (5.15)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="01ca2f07-9bce-e418-e063-6294a90ac760"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Bupivacaine Hydrochloride Injection, USP is a clear, colorless solution available as:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>0.25% (25 mg/10 mL) (2.5 mg/mL) in single-dose teartop vials.</item>
                     <item>0.25% (75 mg/30 mL) (2.5 mg/mL) in single-dose teartop vials.</item>
                     <item>0.25% (125 mg/50 mL) (2.5 mg/mL) in multiple-dose fliptop vials.</item>
                  </list>
                  <list listType="unordered" styleCode="Disc">
                     <item>0.5% (50 mg/10 mL) (5 mg/mL) in single-dose teartop vials.</item>
                     <item>0.5% (150 mg/30 mL) (5 mg/mL) in single-dose teartop vials.</item>
                     <item>0.5% (250 mg/50 mL) (5 mg/mL) in multiple-dose fliptop vials.</item>
                  </list>
                  <list listType="unordered" styleCode="Disc">
                     <item>0.75% (75 mg/10 mL) (7.5 mg/mL) in single-dose teartop vials.</item>
                     <item>0.75% (225 mg/30 mL) (7.5 mg/mL) in single-dose teartop vials.</item>
                  </list>
               </text>
               <effectiveTime value="20230731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Bupivacaine Hydrochloride Injection, USP are available in multiple concentrations. See full prescribing information for detailed description of each formulation. (
 
    <linkHtml href="#S3">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="01ca2f07-9bcf-e418-e063-6294a90ac760"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection is contraindicated in:</paragraph>
                  <list listType="unordered">
                     <item>obstetrical paracervical block anesthesia. Its use in this technique has resulted in fetal bradycardia and death.</item>
                     <item>intravenous regional anesthesia (Bier Block)
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>].
  
   </content>
                     </item>
                     <item>patients with a known hypersensitivity to bupivacaine or to any local anesthetic agent of the amide-type or to other components of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection.</item>
                  </list>
               </text>
               <effectiveTime value="20230731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Obstetrical paracervical block anesthesia. Its use in this technique has resulted in fetal bradycardia and death. (
  
     <linkHtml href="#S4">4</linkHtml>)
 
    </item>
                           <item>Intravenous regional anesthesia (Bier Block). (
  
     <linkHtml href="#S4">4</linkHtml>)
 
    </item>
                           <item>Known hypersensitivity to bupivacaine or to any local anesthetic agent of the amide-type or to other components of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection. (
  
     <linkHtml href="#S4">4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="01ca2f07-9bd0-e418-e063-6294a90ac760"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20230731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Dose-Related Toxicity</content>: Monitor cardiovascular and respiratory vital signs and patient's state of consciousness after injection of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection. (
  
     <linkHtml href="#S5.2">5.2</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Methemoglobinemia</content>: Cases of methemoglobinemia have been reported in association with local anesthetic use. See full prescribing information for more detail on managing these risks. (
  
     <linkHtml href="#S5.3">5.3</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Chondrolysis with Intra-Articular Infusion</content>: Intra-articular infusions of local anesthetics including Bupivacaine Hydrochloride Injection following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of chondrolysis in patients receiving such infusions. (
  
     <linkHtml href="#S5.5">5.5</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Risk of Cardiac Arrest with Intravenous Regional Anesthesia Use (Bier Block)</content>: There have been reports of cardiac arrest and death during the use of bupivacaine for intravenous regional anesthesia (Bier Block). (
  
     <linkHtml href="#S5.7">5.7</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Allergic-Type Reactions to Sulfites in Bupivacaine Hydrochloride and Epinephrine Injection</content>: Bupivacaine Hydrochloride and Epinephrine Injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. (
  
     <linkHtml href="#S5.8">5.8</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Risk of Systemic Toxicities with Unintended Intravascular or Intrathecal Injection</content>: Unintended intravascular or intrathecal injection may be associated with systemic toxicities, including CNS or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Aspirate for blood or cerebrospinal fluid (where applicable) prior to each dose and consider using a test dose of Bupivacaine Hydrochloride and Epinephrine Injection. (
  
     <linkHtml href="#S5.9">5.9</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="01ca2f07-9bd1-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Risk of Cardiac Arrest with Use of Bupivacaine Hydrochloride Injection in Obstetrical Anesthesia</title>
                     <text>
                        <paragraph>There have been reports of cardiac arrest with difficult resuscitation or death during use of Bupivacaine Hydrochloride Injection for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% (7.5 mg/mL) concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. Cardiac arrest has occurred after convulsions resulting from systemic toxicity, presumably following unintentional intravascular injection. The 0.75% (7.5 mg/mL) concentration of Bupivacaine Hydrochloride Injection is not recommended for obstetrical anesthesia and should be reserved for surgical procedures where a high degree of muscle relaxation and prolonged effect are necessary.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="01ca2f07-9bd2-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Dose-Related Toxicity</title>
                     <text>
                        <paragraph>The safety and effectiveness of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies. Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient's state of consciousness should be performed after injection of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection solutions.</paragraph>
                        <paragraph>Possible early warning signs of central nervous system (CNS) toxicity are restlessness, anxiety, incoherent speech, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, dizziness, blurred vision, tremors, twitching, CNS depression, or drowsiness. Delay in proper management of dose-related toxicity, underventilation from any cause, and/or altered sensitivity may lead to the development of acidosis, cardiac arrest, and, possibly, death.</paragraph>
                        <paragraph>During major regional nerve blocks, such as those of the brachial plexus or lower extremity, the patient should have an indwelling intravenous catheter to assure adequate intravenous access. Use the lowest dosage of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection that results in effective anesthesia to avoid high plasma levels and serious adverse effects. Avoid rapid injection of a large volume of Bupivacaine. Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection solution and administer fractional (incremental) doses when feasible.</paragraph>
                        <paragraph>Injection of repeated doses of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection may cause significant increases in plasma levels with each repeated dose due to slow accumulation of the drug or its metabolites, or to slow metabolic degradation. Tolerance to elevated blood levels varies with the status of the patient. Debilitated, elderly patients and acutely ill patients should be given reduced doses commensurate with their age and physical status.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="01ca2f07-9bd3-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Methemoglobinemia</title>
                     <text>
                        <paragraph>Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S7.5">Drug Interactions (7.5)</linkHtml>]
 
  </content>. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.

 </paragraph>
                        <paragraph>Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious CNS and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="01ca2f07-9bd4-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Antimicrobial Preservatives in Multiple-Dose Vials</title>
                     <text>
                        <paragraph>Avoid use of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection solutions containing antimicrobial preservatives, i.e., those supplied in multiple-dose vials, for epidural or caudal anesthesia because safety has not been established with such use.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="01ca2f07-9bd5-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Chondrolysis with Intra-Articular Infusion</title>
                     <text>
                        <paragraph>Intra-articular infusions of local anesthetics including Bupivacaine Hydrochloride Injection following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of chondrolysis in patients receiving such infusions. The majority of reported cases of chondrolysis have involved the shoulder joint; cases of gleno-humeral chondrolysis have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours. There is insufficient information to determine whether shorter infusion periods are associated with chondrolysis. The time of onset of symptoms, such as joint pain, stiffness and loss of motion can be variable, but may begin as early as the 2
 
  <sup>nd</sup>month after surgery. Currently, there is no effective treatment for chondrolysis; patients who experienced chondrolysis have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="01ca2f07-9bd6-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Risk of Adverse Reactions Due to Drug Interactions with Bupivacaine Hydrochloride and Epinephrine Injection</title>
                     <effectiveTime value="20230731"/>
                     <component>
                        <section>
                           <id root="01ca2f07-9bd7-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk of Severe, Persistent Hypertension Due to Drug Interactions Between Bupivacaine Hydrochloride and Epinephrine Injection and Monoamine Oxidase Inhibitors and Tricyclic Antidepressants</content>
                              </paragraph>
                              <paragraph>Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving monoamine oxidase inhibitors (MAOI), or tricyclic antidepressants may result in severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>].
 
  </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="01ca2f07-9bd8-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk of Severe, Persistent Hypertension or Cerebrovascular Accidents Due to Drug Interactions Between Bupivacaine Hydrochloride and Epinephrine Injection and Ergot-Type Oxytocic Drugs</content>
                              </paragraph>
                              <paragraph>Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. Avoid use of Bupivacaine Hydrochloride and Epinephrine Injection concomitantly with ergot-type oxytocic drugs
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S7.3">Drug Interactions (7.3)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="01ca2f07-9bd9-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk of Hypertension and Bradycardia Due to Drug Interactions Between Bupivacaine Hydrochloride and Epinephrine Injection and Nonselective Beta-Adrenergic Antagonists</content>
                              </paragraph>
                              <paragraph>Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S7.4">Drug Interactions (7.4)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="01ca2f07-9bda-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Risk of Cardiac Arrest with Intravenous Regional Anesthesia Use (Bier Block)</title>
                     <text>
                        <paragraph>There have been reports of cardiac arrest and death during the use of bupivacaine for intravenous regional anesthesia (Bier Block). Information on safe dosages and techniques of administration of Bupivacaine Hydrochloride Injection in this procedure is lacking. Therefore, Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection is contraindicated for use with this technique
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S4">Contraindications (4)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="01ca2f07-9bdb-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Allergic-Type Reactions to Sulfites in Bupivacaine Hydrochloride and Epinephrine Injection</title>
                     <text>
                        <paragraph>Bupivacaine Hydrochloride and Epinephrine Injection contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people. Bupivacaine Hydrochloride Injection without epinephrine does not contain sodium metabisulfite.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="01ca2f07-9bdc-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Risk of Systemic Toxicities with Unintended Intravascular or Intrathecal Injection</title>
                     <text>
                        <paragraph>Unintended intravascular or intrathecal injection of. Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection may be associated with systemic toxicities, including CNS or cardiorespiratory depression and coma, progressing ultimately to respiratory arrest. Unintentional intrathecal injection during the intended performance of caudal or lumbar epidural block or nerve blocks near the vertebral column has resulted in underventilation or apnea ("Total or High Spinal"). A high spinal has been characterized by paralysis of the legs, loss of consciousness, respiratory paralysis, and bradycardia
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>Aspirate for blood or cerebrospinal fluid (where applicable) before injecting Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection, both the initial dose and all subsequent doses, to avoid intravascular or intrathecal injection. However, a negative aspiration for blood or cerebrospinal fluid does not ensure against an intravascular or intrathecal injection.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                     <component>
                        <section>
                           <id root="01ca2f07-9bdd-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Use of Test Dose with Epidural Anesthesia</content>
                              </paragraph>
                              <paragraph>To serve as a warning of unintended intravascular or intrathecal injection, 3 mL of Bupivacaine Hydrochloride and Epinephrine Injection without antimicrobial preservative (0.5% bupivacaine with 1:200,000 epinephrine) may be used as a test dose prior to administration of the full dose in caudal and lumbar epidural blocks
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>]
 
  </content>. Three mL of Bupivacaine Hydrochloride and Epinephrine Injection without antimicrobial preservative (0.5% bupivacaine with 1:200,000 epinephrine) contains 15 mg bupivacaine and 15 mcg epinephrine. An intravascular or intrathecal injection is still possible even if results of the test dose are negative.

 </paragraph>
                              <paragraph>Signs/symptoms of unintended intravascular or intrathecal injection of the test dose of Bupivacaine Hydrochloride and Epinephrine Injection and monitoring recommendations are described below.</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Unintended
  
   <content styleCode="italics">intravascular</content>injection: Likely to produce a transient "epinephrine response" within 45 seconds, consisting of an increase in heart rate and/or systolic blood pressure, circumoral pallor, palpitations, and nervousness in the unsedated patient. The sedated patient may exhibit only a pulse rate increase of 20 or more beats per minute for 15 or more seconds. Therefore, following the test dose, the heart rate should be monitored for increases. Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect a transient rise in systolic blood pressure.
 
  </item>
                                 <item>Unintended
  
   <content styleCode="italics">intrathecal</content>injection: Evidenced within a few minutes by signs of spinal block (e.g., decreased sensation of the buttocks, paresis of the legs, or, in the sedated patient, absent knee jerk).
 
  </item>
                              </list>
                              <paragraph>The test dose itself may produce a systemic toxic reaction, high spinal or epinephrine-induced cardiovascular effects
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S10">Overdosage (10)</linkHtml>]
 
  </content>.

 </paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S5.10">
                     <id root="01ca2f07-9bde-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Risk of Toxicity in Patients with Hepatic Impairment</title>
                     <text>
                        <paragraph>Because amide local anesthetics such as bupivacaine are metabolized by the liver, consider reduced dosing and increased monitoring for bupivacaine systemic toxicity in patients with moderate to severe hepatic impairment who are treated Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection, especially with repeat doses
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.11">
                     <id root="01ca2f07-9bdf-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Risk of Use in Patients with Impaired Cardiovascular Function</title>
                     <text>
                        <paragraph>Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection should be given in reduced doses in patients with impaired cardiovascular function (e.g., hypotension, heartblock) because they may be less able to compensate for functional changes associated with the prolongation of AV conduction produced by Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection. Monitor patients closely for blood pressure, heart rate, and ECG changes.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.12">
                     <id root="01ca2f07-9be0-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Risk of Ischemic Injury or Necrosis in Body Areas with Limited Blood Supply</title>
                     <text>
                        <paragraph>Use Bupivacaine Hydrochloride and Epinephrine Injection in carefully restricted quantities in areas of the body supplied by end arteries or having otherwise compromised blood supply such as digits, nose, external ear, or penis. Patients with hypertensive vascular disease may exhibit exaggerated vasoconstrictor response. Ischemic injury or necrosis may result.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.13">
                     <id root="01ca2f07-9be1-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13 Risk of Cardiac Arrhythmias with Concomitant Use of Potent Inhalation Anesthetics</title>
                     <text>
                        <paragraph>Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S7.6">Drug Interactions (7.6)</linkHtml>]
 
  </content>. In deciding whether to concurrently use Bupivacaine Hydrochloride and Epinephrine Injection with potent inhalation anesthetics in the same patient, the combined action of both agents upon the myocardium, the concentration and volume of vasoconstrictor used, and the time since injection, when applicable, should be taken into account.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.14">
                     <id root="01ca2f07-9be2-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.14 Risk of Adverse Reactions with Use in Head and Neck Area</title>
                     <text>
                        <paragraph>Small doses of local anesthetics (e.g., Bupivacaine Hydrochloride Injection) injected into the head and neck area, including retrobulbar, dental, and stellate ganglion blocks, may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injections of larger doses. The injection procedures require the utmost care. Confusion, convulsions, respiratory depression, and/or respiratory arrest, and cardiovascular stimulation or depression have been reported. These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. They may also be due to puncture of the dural sheath of the optic nerve during retrobulbar block with diffusion of any local anesthetic along the subdural space to the midbrain. Monitor circulation and respiration and constantly observe patients receiving Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection blocks. Resuscitative equipment and drugs, and personnel for treating adverse reactions should be immediately available. Dosage recommendations should not be exceeded
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.15">
                     <id root="01ca2f07-9be3-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.15 Risk of Respiratory Arrest with Use in Ophthalmic Surgery</title>
                     <text>
                        <paragraph>Clinicians who perform retrobulbar blocks should be aware that there have been reports of respiratory arrest following local anesthetic injection. Prior to retrobulbar block (e.g., with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection), as with all other regional procedures, resuscitative equipment and drugs, and personnel to manage respiratory arrest or depression, convulsions, and cardiac stimulation or depression should be immediately available
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.14">Warnings and Precautions (5.14)</linkHtml>].
 
  </content>As with other anesthetic procedures, patients should be constantly monitored following ophthalmic blocks for signs of these adverse reactions, which may occur following relatively low total doses.

 </paragraph>
                        <paragraph>A concentration of 0.75% bupivacaine is indicated for retrobulbar block; however, this concentration is not indicated for any other peripheral nerve block, including the facial nerve, and not indicated for local infiltration, including the conjunctiva
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S1">Indications and Usage (1)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.16">
                     <id root="01ca2f07-9be4-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.16 Risk of Inadvertent Trauma to Tongue, Lips, and Buccal Mucosa in Dental Applications</title>
                     <text>
                        <paragraph>Because of the long duration of anesthesia, when Bupivacaine Hydrochloride and Epinephrine Injection [0.5% (5 mg/mL) of bupivacaine] is used for dental injections, warn patients about the possibility of inadvertent trauma to tongue, lips, and buccal mucosa and advise them not to chew solid foods until sensation returns
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S17">Patient Counseling Information (17)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="01ca2f07-9be5-e418-e063-6294a90ac760"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions have been reported and described in the Warnings and Precautions section of the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Cardiac Arrest in Obstetrical Anesthesia
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]
  
   </content>
                     </item>
                     <item>Dose-Related Toxicity
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
  
   </content>
                     </item>
                     <item>Methemoglobinemia
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
  
   </content>
                     </item>
                     <item>Chondrolysis with Intra-Articular Infusion
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml>]
  
   </content>
                     </item>
                     <item>Severe, Persistent Hypertension, Cerebrovascular Accidents, and Bradycardia Due to Drug Interactions
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]
  
   </content>
                     </item>
                     <item>Cardiac Arrest with Intravenous Regional Anesthesia Use
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S4">Contraindications (4)</linkHtml>,
   
    <linkHtml href="#S5.7">Warnings and Precautions (5.7)</linkHtml>]
  
   </content>
                     </item>
                     <item>Allergic-Type Reactions
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]
  
   </content>
                     </item>
                     <item>Systemic Toxicities with Unintended Intravascular or Intrathecal Injection
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>]
  
   </content>
                     </item>
                     <item>Respiratory Arrest Following Retrobulbar Block
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.15">Warnings and Precautions (5.15)</linkHtml>]
  
   </content>
                     </item>
                  </list>
                  <paragraph>The following adverse reactions from voluntary reports or clinical studies have been reported with bupivacaine or bupivacaine and epinephrine. Because many of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>Adverse reactions to Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are characteristic of those associated with other amide-type local anesthetics. A major cause of adverse reactions to this group of drugs is excessive plasma levels, which may be due to overdosage, unintentional intravascular injection, or slow metabolic degradation.</paragraph>
                  <paragraph>The most commonly encountered acute adverse reactions that demand immediate counter-measures were related to the CNS and the cardiovascular system. These adverse reactions were generally dose-related and due to high plasma levels which may have resulted from overdosage, rapid absorption from the injection site, diminished tolerance, or from unintentional intravascular injection of the local anesthetic solution. In addition to systemic dose-related toxicity, unintentional intrathecal injection of drug during the intended performance of caudal or lumbar epidural block or nerve blocks near the vertebral column (especially in the head and neck region) has resulted in underventilation or apnea ("Total or High Spinal"). Also, hypotension due to loss of sympathetic tone and respiratory paralysis or underventilation due to cephalad extension of the motor level of anesthesia have occurred. This has led to secondary cardiac arrest when untreated.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions are related to the central nervous system and the cardiovascular system. (
 
    <linkHtml href="#S6">6</linkHtml>)

   </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section>
                     <id root="01ca2f07-9be6-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Nervous System Disorders</content>
                        </paragraph>
                        <paragraph>Adverse reactions were characterized by excitation and/or depression of the central nervous system and included restlessness, anxiety, dizziness, tinnitus, blurred vision, tremors, convulsions, drowsiness, unconsciousness, respiratory arrest, nausea, vomiting, chills, pupillary constriction.</paragraph>
                        <paragraph>In the practice of caudal or lumbar epidural block, unintentional penetration of the subarachnoid space by the catheter or needle has occurred. Subsequent adverse effects may have depended partially on the amount of drug administered intrathecally and the physiological and physical effects of a dural puncture. A high spinal has been characterized by paralysis of the legs, loss of consciousness, respiratory paralysis, and bradycardia.</paragraph>
                        <paragraph>Neurologic effects following epidural or caudal anesthesia have included spinal block of varying magnitude (including high or total spinal block); hypotension secondary to spinal block; urinary retention; fecal and urinary incontinence; loss of perineal sensation and sexual function; persistent anesthesia, paresthesia, weakness, paralysis of the lower extremities and loss of sphincter control, all of which had slow, incomplete, or no recovery; headache; backache; septic meningitis; meningismus; slowing of labor; increased incidence of forceps delivery; and cranial nerve palsies due to traction on nerves from loss of cerebrospinal fluid.</paragraph>
                        <paragraph>Neurologic effects following other procedures or routes of administration have included persistent anesthesia, paresthesia, weakness, paralysis, all with slow, incomplete, or no recovery.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                     <component>
                        <section>
                           <id root="01ca2f07-9be7-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Convulsions</content>: Incidence varied with the procedure used and the total dose administered. In a survey of studies of epidural anesthesia, overt toxicity progressing to convulsions occurred in approximately 0.1% of local anesthetic administrations. The incidences of adverse neurologic reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration, and the physical status of the patient.

 </paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="01ca2f07-9be8-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Cardiac Disorders</content>
                        </paragraph>
                        <paragraph>High doses or unintentional intravascular injection have led to high plasma levels and related depression of the myocardium, decreased cardiac output, heartblock, hypotension, bradycardia, ventricular arrhythmias, including ventricular tachycardia and ventricular fibrillation, and cardiac arrest
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="01ca2f07-9be9-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Immune System Disorders</content>
                        </paragraph>
                        <paragraph>Allergic-type reactions have occurred as a result of sensitivity to bupivacaine or to other formulation ingredients, such as the antimicrobial preservative methylparaben contained in multiple-dose vials or sulfites in epinephrine-containing solutions. These reactions were characterized by signs such as urticaria, pruritus, erythema, angioneurotic edema (including laryngeal edema), tachycardia, sneezing, nausea, vomiting, dizziness, syncope, excessive sweating, elevated temperature, and severe hypotension. Cross sensitivity among members of the amide-type local anesthetic group has been reported
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="01ca2f07-9bea-e418-e063-6294a90ac760"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20230731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Local Anesthetics</content>: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. (
  
     <linkHtml href="#S7.1">7.1</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Monoamine Oxidase Inhibitors and Tricyclic Antidepressants</content>: Administration of Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. (
  
     <linkHtml href="#S5.6">5.6</linkHtml>,
  
     <linkHtml href="#S7.2">7.2</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Ergot-Type Oxytocic Drugs</content>: Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (
  
     <linkHtml href="#S5.6">5.6</linkHtml>,
  
     <linkHtml href="#S7.3">7.3</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Nonselective Beta-Adrenergic Antagonists</content>: Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. Concurrent use of these agents should generally be avoided. (
  
     <linkHtml href="#S5.6">5.6</linkHtml>,
  
     <linkHtml href="#S7.4">7.4</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Drugs Associated with Methemoglobinemia</content>: Patients are at increased risk of developing methemoglobinemia when concurrently exposed to nitrates, nitrites, local anesthetics, antineoplastic agents, antibiotics, antimalarials, anticonvulsants, and other drugs. (
  
     <linkHtml href="#S7.5">7.5</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Potent Inhalation Anesthetics</content>: Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine are used in patients during or following the administration of potent inhalation anesthetics. (
  
     <linkHtml href="#S5.13">5.13</linkHtml>,
  
     <linkHtml href="#S7.6">7.6</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="01ca2f07-9beb-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Local Anesthetics</title>
                     <text>
                        <paragraph>The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.1">Dosage and Administration (2.1)</linkHtml>,
  
   <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="01ca2f07-9bec-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants</title>
                     <text>
                        <paragraph>The administration Bupivacaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patient's hemodynamic status is essential
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="01ca2f07-9bed-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Ergot-Type Oxytocic Drugs</title>
                     <text>
                        <paragraph>Concurrent administration of Bupivacaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. Avoid use of Bupivacaine Hydrochloride and Epinephrine concomitantly with ergot-type oxytocic drugs
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.4">
                     <id root="01ca2f07-9bee-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Nonselective Beta-Adrenergic Antagonists</title>
                     <text>
                        <paragraph>Administration of Bupivacaine Hydrochloride and Epinephrine Injection (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patient's blood pressure and heart rate is essential
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.6">Warnings and Precautions (5.6)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.5">
                     <id root="01ca2f07-9bef-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5 Drugs Associated with Methemoglobinemia</title>
                     <text>
                        <paragraph>Patients who are administered Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are at increased risk of developing methemoglobinemia when concurrently exposed to following drugs, which could include other local anesthetics
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]
 
  </content>.

 </paragraph>
                        <table width="90%">
                           <caption>Examples of Drugs Associated with Methemoglobinemia:</caption>
                           <col width="30%" align="left" valign="top"/>
                           <col width="70%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Class</th>
                                 <th styleCode="Rrule">Examples</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Nitrates/Nitrites</td>
                                 <td styleCode="Rrule">nitric oxide, nitroglycerin, nitroprusside, nitrous oxide</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Local anesthetics</td>
                                 <td styleCode="Rrule">articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Antineoplastic agents</td>
                                 <td styleCode="Rrule">cyclophosphamide, flutamide, hydroxyurea, isofamide, rasburicase</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Antibiotics</td>
                                 <td styleCode="Rrule">dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Antimalarials</td>
                                 <td styleCode="Rrule">chloroquine, primaquine</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Anticonvulsants</td>
                                 <td styleCode="Rrule">phenobarbital, phenytoin, sodium valproate</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Other drugs</td>
                                 <td styleCode="Rrule">acetaminophen, metoclopramide, quinine, sulfasalazine</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.6">
                     <id root="01ca2f07-9bf0-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.6 Potent Inhalation Anesthetics</title>
                     <text>
                        <paragraph>Serious dose-related cardiac arrhythmias may occur if preparations containing a vasoconstrictor such as epinephrine (e.g., Bupivacaine Hydrochloride and Epinephrine Injection) are used in patients during or following the administration of potent inhalation anesthetics
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.13">Warnings and Precautions (5.13)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.7">
                     <id root="01ca2f07-9bf1-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.7 Phenothiazines and Butyrophenones</title>
                     <text>
                        <paragraph>Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. Concurrent use of Bupivacaine Hydrochloride and Epinephrine Injection and these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="01ca2f07-9bf2-e418-e063-6294a90ac760"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20230731"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Pediatric Use</content>: Administration of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection in pediatric patients younger than 12 years is not recommended. (
  
     <linkHtml href="#S8.4">8.4</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Geriatric Use</content>: Patients 65 years and over, particularly those with hypertension, may be at increased risk for developing hypotension while undergoing anesthesia with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection. (
  
     <linkHtml href="#S8.5">8.5</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Moderate to Severe Hepatic Impairment</content>: Consider increased monitoring for bupivacaine systemic toxicity. (
  
     <linkHtml href="#S8.6">8.6</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="01ca2f07-9bf3-e418-e063-6294a90ac760"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20230731"/>
                     <component>
                        <section>
                           <id root="01ca2f07-9bf4-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection is contraindicated for obstetrical paracervical block anesthesia. Its use in this technique has resulted in fetal bradycardia and death
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S4">Contraindications (4)</linkHtml>,
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].
 
  </content>
                              </paragraph>
                              <paragraph>There are no available data on use of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection in pregnant women to inform a drug-associated risk of adverse developmental outcomes.</paragraph>
                              <paragraph>In animal studies, embryo-fetal lethality was noted when bupivacaine was administered subcutaneously to pregnant rabbits during organogenesis at clinically relevant doses. Decreased pup survival was observed in a rat pre- and post-natal developmental study (dosing from implantation through weaning) at a dose level comparable to the daily maximum recommended human dose (MRHD) on a body surface area (BSA) basis. Based on animal data, advise pregnant women of the potential risks to a fetus
 
  <content styleCode="italics">(see
  
   <linkHtml href="#DATA">Data</linkHtml>).
 
  </content>
                              </paragraph>
                              <paragraph>Local anesthetics rapidly cross the placenta, and when used for epidural, caudal, or pudendal block anesthesia, can cause varying degrees of maternal, fetal, and neonatal toxicity
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].
 
  </content>The incidence and degree of toxicity depend upon the procedure performed, the type, and amount of drug used, and the technique of drug administration. Adverse reactions in the parturient, fetus, and neonate involve alterations of the CNS, peripheral vascular tone, and cardiac function.

 </paragraph>
                              <paragraph>If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, inform the patient of the potential hazard to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="01ca2f07-9bf5-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                           <component>
                              <section>
                                 <id root="01ca2f07-9bf6-e418-e063-6294a90ac760"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Maternal Adverse Reactions</content>
                                    </paragraph>
                                    <paragraph>Maternal hypotension has resulted from regional anesthesia. Local anesthetics produce vasodilation by blocking sympathetic nerves. The supine position is dangerous in pregnant women at term because of aortocaval compression by the gravid uterus. Therefore, during treatment of systemic toxicity, maternal hypotension or fetal bradycardia following regional block, the parturient should be maintained in the left lateral decubitus position if possible, or manual displacement of the uterus off the great vessels be accomplished. Elevating the patient's legs will also help prevent decreases in blood pressure. The fetal heart rate also should be monitored continuously and electronic fetal monitoring is highly advisable.</paragraph>
                                 </text>
                                 <effectiveTime value="20230731"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="01ca2f07-9bf7-e418-e063-6294a90ac760"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Labor or Delivery</content>
                                    </paragraph>
                                    <paragraph>Epidural, caudal, or pudendal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts. Epidural anesthesia has been reported to prolong the second stage of labor by removing the parturient's reflex urge to bear down or by interfering with motor function. The use of obstetrical anesthesia may increase the need for forceps assistance.</paragraph>
                                    <paragraph>The use of some local anesthetic drug products during labor and delivery may be followed by diminished muscle strength and tone for the first day or two of life. This has not been reported with bupivacaine.</paragraph>
                                    <paragraph>It is extremely important to avoid aortocaval compression by the gravid uterus during administration of regional block to parturients. To do this, the patient must be maintained in the left lateral decubitus position or a blanket roll or sandbag may be placed beneath the right hip and gravid uterus displaced to the left.</paragraph>
                                 </text>
                                 <effectiveTime value="20230731"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="DATA">
                           <id root="01ca2f07-9bf8-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                           <component>
                              <section>
                                 <id root="01ca2f07-9bf9-e418-e063-6294a90ac760"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Bupivacaine hydrochloride produced developmental toxicity when administered subcutaneously to pregnant rats and rabbits at clinically relevant doses.</paragraph>
                                    <paragraph>Bupivacaine hydrochloride was administered subcutaneously to rats at doses of 4.4, 13.3, &amp; 40 mg/kg and to rabbits at doses of 1.3, 5.8, &amp; 22.2 mg/kg during the period of organogenesis (implantation to closure of the hard palate). The high doses are comparable to the daily MRHD of 400 mg/day on a mg/m
 
  <sup>2</sup>BSA basis. No embryo-fetal effects were observed in rats at the high dose which caused increased maternal lethality. An increase in embryo-fetal deaths was observed in rabbits at the high dose in the absence of maternal toxicity with the fetal No Observed Adverse Effect Level representing approximately 0.3 times the MRHD on a BSA basis.

 </paragraph>
                                    <paragraph>In a rat pre-and post-natal developmental study (dosing from implantation through weaning) conducted at subcutaneous doses of 4.4, 13.3, &amp; 40 mg/kg, decreased pup survival was observed at the high dose. The high dose is comparable to the daily MRHD of 400 mg/day on a BSA basis.</paragraph>
                                 </text>
                                 <effectiveTime value="20230731"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2a">
                     <id root="01ca2f07-9bfa-e418-e063-6294a90ac760"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20230731"/>
                     <component>
                        <section>
                           <id root="01ca2f07-9bfb-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Lactation studies have not been conducted with bupivacaine. Bupivacaine has been reported to be excreted in human milk suggesting that the nursing infant could be theoretically exposed to a dose of the drug. Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection should be administered to lactating women only if clearly indicated. Studies assessing the effects of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection in breastfed children have not been performed. Studies to assess the effect of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection on milk production or excretion have not been performed. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for bupivacaine and any potential adverse effects on the breastfed child from bupivacaine or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="01ca2f07-9bfc-e418-e063-6294a90ac760"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection is approved for use in adults. Administration of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection in pediatric patients younger than 12 years is not recommended.</paragraph>
                        <paragraph>Continuous infusions of bupivacaine in pediatric patients have been reported to result in high systemic levels of bupivacaine and seizures; high plasma levels may also be associated with cardiovascular abnormalities.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="01ca2f07-9bfd-e418-e063-6294a90ac760"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Patients 65 years and over, particularly those with hypertension, may be at increased risk for developing hypotension while undergoing anesthesia with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection.</paragraph>
                        <paragraph>In clinical studies of bupivacaine, elderly patients reached the maximal spread of analgesia and maximal motor blockade more rapidly than younger adult patients.</paragraph>
                        <paragraph>Differences in various pharmacokinetic parameters have been observed between elderly and younger adult patients
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].
 
  </content>
                        </paragraph>
                        <paragraph>This product is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. Elderly patients may require lower doses of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="01ca2f07-9bfe-e418-e063-6294a90ac760"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph>Amide-type local anesthetics, such as bupivacaine, are metabolized by the liver. Patients with severe hepatic impairment, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations, and potentially local anesthetic systemic toxicity. Therefore, consider reduced dosing and increased monitoring for local anesthetic systemic toxicity in patients with moderate to severe hepatic impairment treated with Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection, especially with repeat doses
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.10">Warnings and Precautions (5.10)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="01ca2f07-9bff-e418-e063-6294a90ac760"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph>Bupivacaine is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with renal impairment. This should be considered when selecting the Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection dosage
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="01ca2f07-9c00-e418-e063-6294a90ac760"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <effectiveTime value="20230731"/>
               <component>
                  <section>
                     <id root="01ca2f07-9c01-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Clinical Presentation</content>
                        </paragraph>
                        <paragraph>Acute emergencies from use of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection are generally related to high plasma levels encountered during therapeutic use or to unintended intrathecal injection
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>,
  
   <linkHtml href="#S5.9">5.9)</linkHtml>,
  
   <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>].
 
  </content>
                        </paragraph>
                        <paragraph>If not treated immediately, convulsions with simultaneous hypoxia, hypercarbia, and acidosis plus myocardial depression from the direct effects of bupivacaine may result in cardiac arrhythmias, bradycardia, asystole, ventricular fibrillation, or cardiac arrest. Respiratory abnormalities, including apnea, may occur. Hypoventilation or apnea due to unintentional intrathecal injection of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection may produce these same signs and also lead to cardiac arrest if ventilatory support is not instituted. If cardiac arrest should occur, successful outcome may require prolonged resuscitative efforts.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="01ca2f07-9c02-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Management</content>
                        </paragraph>
                        <paragraph>The first step in the management of systemic toxic reactions, as well as hypoventilation or apnea due to unintentional intrathecal injection of Bupivacaine Hydrochloride Injection/Bupivacaine Hydrochloride and Epinephrine Injection, consists of
 
  <content styleCode="underline">immediate</content>attention to the establishment and maintenance of a patent airway and effective assisted or controlled ventilation with 100% oxygen with a delivery system capable of permitting immediate positive airway pressure by mask. Endotracheal intubation, using drugs and techniques familiar to the clinician, may be indicated after initial administration of oxygen by mask if difficulty is encountered in the maintenance of a patent airway, or if prolonged ventilatory support (assisted or controlled) is indicated.

 </paragraph>
                        <paragraph>If necessary, use drugs to manage the convulsions. A bolus intravenous dose of a benzodiazepine will counteract CNS stimulation related to Bupivacaine Hydrochloride Injection. Immediately after the institution of ventilatory measures, evaluate the adequacy of the circulation. Supportive treatment of circulatory depression may require Advance Cardiac Life Support measures.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="01ca2f07-9c03-e418-e063-6294a90ac760"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Bupivacaine Hydrochloride Injection contains bupivacaine hydrochloride, an amide local anesthetic, as the active pharmaceutical ingredient. The route of administration for Bupivacaine Hydrochloride Injection (without epinephrine) is by injection, for infiltration, perineural, caudal, epidural, or retrobulbar use. Multiple-dose vials contain methylparaben
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]
 
  </content>.

 </paragraph>
                  <paragraph>Bupivacaine hydrochloride is 2-piperidinecarboxamide, 1-butyl-
 
  <content styleCode="italics">N</content>-(2,6-dimethylphenyl)-, monohydrochloride, monohydrate. It is a white crystalline powder that is freely soluble in 95 percent ethanol, soluble in water, and slightly soluble in chloroform or acetone. It has the following structural formula:

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L448f2738-9181-4fcc-8f73-c0c7605630dd"/>
                  </paragraph>
                  <paragraph>Bupivacaine Hydrochloride Injection, USP is a clear and colorless sterile isotonic solution. Each mL of single-dose vial contains 2.5 mg, 5 mg, or 7.5 mg of bupivacaine hydrochloride (equivalent to 2.22 mg, 4.44 mg, or 6.66 mg of bupivacaine, respectively), sodium chloride for isotonicity, sodium hydroxide or hydrochloric acid to adjust the pH between 4 and 6.5, in water for injection.</paragraph>
                  <paragraph>For the multiple-dose vials, each mL also contains 1 mg methylparaben as preservative.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
               <component>
                  <observationMedia ID="L448f2738-9181-4fcc-8f73-c0c7605630dd">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dyu01-0004-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="01ca2f07-9c04-e418-e063-6294a90ac760"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20230731"/>
               <component>
                  <section ID="S12.1">
                     <id root="01ca2f07-9c05-e418-e063-6294a90ac760"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: (1) pain, (2) temperature, (3) touch, (4) proprioception, and (5) skeletal muscle tone.</paragraph>
                        <paragraph>Epinephrine is a vasoconstrictor added to bupivacaine to slow absorption into the general circulation and thus prolong maintenance of an active tissue concentration.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="01ca2f07-9c06-e418-e063-6294a90ac760"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Systemic absorption of bupivacaine produces effects on the cardiovascular system and CNS. At blood concentrations achieved with normal therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, toxic blood concentrations depress cardiac conduction and excitability, which may lead to atrioventricular block, ventricular arrhythmias, and cardiac arrest, sometimes resulting in fatalities. In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure. These cardiovascular changes are more likely to occur after unintended intravascular injection of bupivacaine
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.9">Warnings and Precautions (5.9)</linkHtml>]
 
  </content>.

 </paragraph>
                        <paragraph>Following systemic absorption, bupivacaine can produce CNS stimulation, CNS depression, or both. Apparent central stimulation is manifested as restlessness, tremors, and shivering, progressing to convulsions, followed by CNS depression and coma progressing ultimately to respiratory arrest. However, bupivacaine has a primary depressant effect on the medulla and on higher centers. The depressed stage may occur without a prior excited state.</paragraph>
                        <paragraph>The duration of local anesthesia after administration of Bupivacaine Hydrochloride Injection is longer than that observed after administration of other commonly used short-acting local anesthetics. There appears to be period of analgesia that persists after the resolution of the block and return of sensation.</paragraph>
                        <paragraph>The onset of action following dental injections is usually 2 to 10 minutes and may last up to 7 hours. The duration of anesthetic effect is prolonged by the addition of epinephrine 1:200,000.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="01ca2f07-9c07-e418-e063-6294a90ac760"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Systemic plasma levels of bupivacaine following administration of Bupivacaine Hydrochloride Injection do not correlate with local efficacy.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                     <component>
                        <section>
                           <id root="01ca2f07-9c08-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>The rate of systemic absorption of bupivacaine is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic solution. A dilute concentration of epinephrine (1:200,000) usually reduces the rate of absorption and peak plasma concentration of bupivacaine, permitting the use of moderately larger total doses and sometimes prolonging the duration of action
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2">Dosage and Administration (2)</linkHtml>]
 
  </content>.

 </paragraph>
                              <paragraph>After injection of Bupivacaine Hydrochloride Injection for caudal, epidural, or peripheral nerve block, peak levels of bupivacaine in the blood are reached in 30 to 45 minutes, followed by a decline to insignificant levels during the next three to six hours.</paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="01ca2f07-9c09-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Bupivacaine appears to cross the placenta by passive diffusion. The rate and degree of diffusion is governed by (1) the degree of plasma protein binding, (2) the degree of ionization, and (3) the degree of lipid solubility. Fetal/maternal ratios of bupivacaine appear to be inversely related to the degree of plasma protein binding, because only the free, unbound drug is available for placental transfer. Bupivacaine with a high protein binding capacity (95%) has a low fetal/maternal ratio (0.2 to 0.4). The extent of placental transfer is also determined by the degree of ionization and lipid solubility of the drug. Lipid soluble, nonionized drugs readily enter the fetal blood from the maternal circulation.</paragraph>
                              <paragraph>Depending upon the route of administration, bupivacaine is distributed to some extent to all body tissues, with high concentrations found in highly perfused organs such as the liver, lungs, heart, and brain.</paragraph>
                              <paragraph>Pharmacokinetic studies on the plasma profile of bupivacaine after direct intravenous injection (Bupivacaine Hydrochloride Injection is not approved for intravenous use) suggest a three-compartment open model. The first compartment is represented by the rapid intravascular distribution of the drug. The second compartment represents the equilibration of the drug throughout the highly perfused organs such as the brain, myocardium, lungs, kidneys, and liver. The third compartment represents an equilibration of the drug with poorly perfused tissues, such as muscle and fat.</paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="01ca2f07-9c0a-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The half-life of bupivacaine in adults is 2.7 hours.</paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                           <component>
                              <section>
                                 <id root="01ca2f07-9c0b-e418-e063-6294a90ac760"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Amide-type local anesthetics such as bupivacaine are metabolized primarily in the liver via conjugation with glucuronic acid. Pipecoloxylidine is the major metabolite of bupivacaine. The elimination of drug from tissue distribution depends largely upon the availability of binding sites in the circulation to carry it to the liver where it is metabolized.</paragraph>
                                 </text>
                                 <effectiveTime value="20230731"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="01ca2f07-9c0c-e418-e063-6294a90ac760"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>The kidney is the main excretory organ for most local anesthetics and their metabolites. Urinary excretion is affected by urinary perfusion and factors affecting urinary pH. Only 6% of bupivacaine is excreted unchanged in the urine.</paragraph>
                                 </text>
                                 <effectiveTime value="20230731"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="01ca2f07-9c0d-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                           <component>
                              <section>
                                 <id root="01ca2f07-9c0e-e418-e063-6294a90ac760"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Geriatric Patients</content>
                                    </paragraph>
                                    <paragraph>Elderly patients exhibited higher peak plasma concentrations than younger patients following administration of Bupivacaine Hydrochloride Injection. The total plasma clearance was decreased in these patients
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>]
 
  </content>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230731"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="01ca2f07-9c0f-e418-e063-6294a90ac760"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment</content>
                                    </paragraph>
                                    <paragraph>Various pharmacokinetic parameters of the local anesthetics can be significantly altered by the presence of hepatic disease. Patients with hepatic disease, especially those with severe hepatic disease, may be more susceptible to the potential toxicities of the amide-type local anesthetics
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>]
 
  </content>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230731"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="01ca2f07-9c10-e418-e063-6294a90ac760"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment</content>
                                    </paragraph>
                                    <paragraph>Various pharmacokinetic parameters of the local anesthetics can be significantly altered by the presence of renal disease, factors affecting urinary pH, and renal blood flow
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.5">Use in Specific Populations (8.5</linkHtml>,
  
   <linkHtml href="#S8.7">8.7)</linkHtml>]
 
  </content>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230731"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="01ca2f07-9c11-e418-e063-6294a90ac760"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20230731"/>
               <component>
                  <section ID="S13.1">
                     <id root="01ca2f07-9c12-e418-e063-6294a90ac760"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20230731"/>
                     <component>
                        <section>
                           <id root="01ca2f07-9c13-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Long-term studies in animals to evaluate the carcinogenic potential of bupivacaine hydrochloride have not been conducted.</paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="01ca2f07-9c14-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>The mutagenic potential of bupivacaine hydrochloride has not been determined.</paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="01ca2f07-9c15-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>The effect of bupivacaine on fertility has not been determined.</paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="01ca2f07-9c16-e418-e063-6294a90ac760"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20230731"/>
               <component>
                  <section>
                     <id root="01ca2f07-9c17-e418-e063-6294a90ac760"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store at 20 °C to 25 °C (68 °F to 77 °F); excursions permitted between 15 °C to 30 °C (59 °F to 86 °F). [See USP Controlled Room Temperature.]</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="id_link_01ccbd5d-c8ae-e3c5-e063-6394a90adbe4">
                     <id root="01ccbd5d-c8ad-e3c5-e063-6394a90adbe4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Bupivacaine Hydrochloride Injection, USP</content>─ Solutions of bupivacaine hydrochloride that do not contain epinephrine may be autoclaved. Autoclave at 15-pound pressure, 121 °C (250 °F) for 15 minutes. This product is clear and colorless. Do not use the solution if it is discolored or if it contains a precipitate.
 </paragraph>
                        <table width="90%">
                           <colgroup>
                              <col align="left" valign="top" width="50%"/>
                              <col align="center" valign="top" width="50%"/>
                           </colgroup>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Unit of Sale</th>
                                 <th styleCode="Rrule">Concentration</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">NDC 0409-1159-01</content>
                                    <br/>
			Tray of 25 single-dose teartop vials
    </td>
                                 <td styleCode="Rrule">0.25%
     <br/>
                                    <content styleCode="bold">25 mg/10 mL</content>
                                    <br/>
			(2.5 mg/mL)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">NDC 0409-1159-02</content>
                                    <br/>
			Tray of 25 single-dose teartop vials
    </td>
                                 <td styleCode="Rrule">0.25%
     <br/>
                                    <content styleCode="bold">75 mg/30 mL</content>
                                    <br/>
			(2.5 mg/mL)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">NDC 0409-1160-01</content>
                                    <br/>
			Tray of 25 multiple-dose fliptop vials
    </td>
                                 <td styleCode="Rrule">0.25%
     <br/>
                                    <content styleCode="bold">125 mg/50 mL</content>
                                    <br/>
			(2.5 mg/mL)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">NDC 0409-1163-01</content>
                                    <br/>
			Tray of 25 multiple-dose fliptop vials
    </td>
                                 <td styleCode="Rrule">0.5%
     <br/>
                                    <content styleCode="bold">250 mg/50 mL</content>
                                    <br/>
			(5 mg/mL)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">NDC 0409-1162-01</content>
                                    <br/>
			Tray of 25 single-dose teartop vials
    </td>
                                 <td styleCode="Rrule">0.5%
     <br/>
                                    <content styleCode="bold">50 mg/10 mL</content>
                                    <br/>
			(5 mg/mL)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">NDC 0409-1162-02</content>
                                    <br/>
			Tray of 25 single-dose teartop vials
    </td>
                                 <td styleCode="Rrule">0.5%
     <br/>
                                    <content styleCode="bold">150 mg/30 mL</content>
                                    <br/>
			(5 mg/mL)
    </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">NDC 0409-1165-01</content>
                                    <br/>
			Tray of 25 single-dose teartop vials
    </td>
                                 <td styleCode="Rrule">0.75%
     <br/>
                                    <content styleCode="bold">75 mg/10 mL</content>
                                    <br/>
			(7.5 mg/mL)
    </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">NDC 0409-1165-02</content>
                                    <br/>
			Tray of 25 single-dose teartop vials
    </td>
                                 <td styleCode="Rrule">0.75%
     <br/>
                                    <content styleCode="bold">225 mg/30 mL</content>
                                    <br/>
			(7.5 mg/mL)
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>For single-dose vials: Discard unused portion.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="01ca2f07-9c19-e418-e063-6294a90ac760"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20230731"/>
               <component>
                  <section>
                     <id root="01ca2f07-9c1a-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Allergic-Type Reactions</content>
                        </paragraph>
                        <paragraph>Assess if the patient has had allergic-type reactions to amide-type local anesthetics or to other formulation ingredients, such as the antimicrobial preservative methylparaben contained in multiple-dose vials or sulfites in epinephrine-containing solutions
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S4">Contraindications (4)</linkHtml>,
  
   <linkHtml href="#S5.8">Warnings and Precautions (5.8)</linkHtml>,
  
   <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="01ca2f07-9c1b-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Temporary Loss of Sensation and Motor Activity After Caudal or Epidural Anesthesia</content>
                        </paragraph>
                        <paragraph>When appropriate, patients should be informed in advance that they may experience temporary loss of sensation and motor activity, usually in the lower half of the body, following proper administration of caudal or epidural anesthesia.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="01ca2f07-9c1c-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Instructions After Dental Injection of Bupivacaine Hydrochloride Injection</content>
                        </paragraph>
                        <paragraph>Advise patients receiving dental injections of Bupivacaine Hydrochloride Injection not to chew solid foods or to test the anesthetized area by biting or probing until anesthesia has worn off (up to 7 hours)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.16">Warnings and Precautions (5.16)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="01ca2f07-9c1d-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Methemoglobinemia</content>
                        </paragraph>
                        <paragraph>Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="01ca2f07-9c1e-e418-e063-6294a90ac760"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>This product's labeling may have been updated. For the most recent prescribing information, please visit www.pfizer.com.</paragraph>
                  <paragraph>Distributed by Hospira, Inc., Lake Forest, IL 60045 USA</paragraph>
                  <paragraph>LAB-1176-5.0</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="L48e71a18-9d7a-450d-9b6f-7d81ae5764ea">
               <id root="01ca2f07-9c1f-e418-e063-6294a90ac760"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Methylprednisolone Acetate Injectable Suspension, USP</content>
                     <br/>
                     <content styleCode="bold">80 mg/mL (1 mL)</content>
                     <br/>
                     <content styleCode="bold">Rx only</content>
                     <br/>
                     <content styleCode="bold">Single-Dose Vial</content>
                     <br/>
                     <content styleCode="bold">Not For Intravenous Use</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="d1">
               <id root="01ca2f07-9c20-e418-e063-6294a90ac760"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Methylprednisolone acetate injectable suspension, USP is an anti-inflammatory glucocorticoid for intramuscular, intra-articular, soft tissue or intralesional injection. It is available as single-dose vials in 80 mg/mL strength</paragraph>
                  <paragraph>Each mL of these preparations contains:</paragraph>
                  <table width="100.0%" cellspacing="0" cellpadding="0" border="1">
                     <tbody>
                        <tr>
                           <td>
                              <paragraph>##</paragraph>
                           </td>
                           <td>
                              <paragraph>
                                 <content styleCode="bold">80 mg/mL</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>Methylprednisolone Acetate, USP</paragraph>
                           </td>
                           <td>
                              <paragraph>80 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>Polyethylene glycol 3350</paragraph>
                           </td>
                           <td>
                              <paragraph>28 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <paragraph>Myristyl-gamma-picolinium chloride</paragraph>
                           </td>
                           <td>
                              <paragraph>0.189 mg</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph/>
                  <paragraph>Sodium chloride was added to adjust tonicity.</paragraph>
                  <paragraph>When necessary, pH was adjusted with sodium hydroxide and/or hydrochloric acid.</paragraph>
                  <paragraph>The pH of the finished product remains within the USP specified range (e.g., 3.0 to 7.0).</paragraph>
                  <paragraph>The chemical name for methylprednisolone acetate is pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11,17-dihydroxy-6-methyl-,(6α,11β)- and the molecular weight is 416.51. The structural formula is represented below:</paragraph>
                  <paragraph/>
                  <paragraph>
                     <renderMultiMedia referencedObject="L87917120-eb0a-448a-b588-a3a422be6166"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>Methylprednisolone acetate injectable suspension, USP contains methylprednisolone acetate, USP which is the 6-methyl derivative of prednisolone. Methylprednisolone acetate, USP is a white or almost white crystalline powder which melts at about 213° with some decomposition. It is soluble in dioxane, sparingly soluble in acetone, alcohol, chloroform, and methanol, and slightly soluble in ether. It is practically insoluble in water.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
               <component>
                  <observationMedia ID="L87917120-eb0a-448a-b588-a3a422be6166">
                     <text>image description</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dyu01-0004-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e27b108f-7874-4771-b484-fd699d8bf3f5">
               <id root="01ca2f07-9c21-e418-e063-6294a90ac760"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids.</paragraph>
                  <paragraph>Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt retaining properties, are used in replacement therapy in adrenocortical deficiency states. Their synthetic analogs are used primarily for their anti-inflammatory effects in disorders of many organ systems.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="LINK_2fcebdfd-57ff-467a-a9c4-81bcd2ec7781">
               <id root="01ca2f07-9c22-e418-e063-6294a90ac760"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">A. For Intramuscular Administration</content>
                  </paragraph>
                  <paragraph>When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows:</paragraph>
                  <paragraph>
                     <content styleCode="italics">Allergic States</content>: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Dermatologic Diseases</content>: Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Endocrine Disorders</content>: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal Diseases</content>: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Hematologic Disorders</content>: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Miscellaneous</content>: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Neoplastic Diseases</content>: For palliative management of: leukemias and lymphomas.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Nervous System</content>: Cerebral edema associated with primary or metastatic brain tumor or craniotomy.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Ophthalmic Diseases</content>: Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Renal Diseases</content>: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Respiratory Diseases</content>: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Rheumatic Disorders</content>: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">B. For Intra-articular Or Soft Tissue Administration</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">(</content>See
 
  <content styleCode="bold">
                        <linkHtml href="#LINK_86809099-c76f-4f42-8f43-de62e31b9218">WARNINGS</linkHtml>)
 
  </content>
                  </paragraph>
                  <paragraph>Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis.</paragraph>
                  <paragraph>
                     <content styleCode="bold">C. For Intralesional Administration</content>
                  </paragraph>
                  <paragraph>Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum.</paragraph>
                  <paragraph>Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia).</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="LINK_cb64d219-4c1b-4230-aa26-3cb55f243c8c">
               <id root="01ca2f07-9c23-e418-e063-6294a90ac760"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Methylprednisolone acetate injectable suspension is contraindicated in patients with known hypersensitivity to the product and its constituents.</paragraph>
                  <paragraph>Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura. 
  <br/>  Methylprednisolone acetate injectable suspension is contraindicated for intrathecal administration. This formulation of methylprednisolone acetate has been associated with reports of severe medical events when administered by this route.
 </paragraph>
                  <paragraph>Methylprednisolone acetate injectable suspension is contraindicated in systemic fungal infections, except when administered as an intra-articular injection for localized joint conditions (see
 
  <content styleCode="bold">
                        <linkHtml href="#LINK_86809099-c76f-4f42-8f43-de62e31b9218">WARNINGS</linkHtml>: Infections,
  
   <content styleCode="italics">Fungal Infections</content>
                     </content>).

 </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="LINK_86809099-c76f-4f42-8f43-de62e31b9218">
               <id root="01ca2f07-9c24-e418-e063-6294a90ac760"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Serious Neurologic Adverse Reactions with Epidural Administration</content>
                  </paragraph>
                  <paragraph>Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use.</paragraph>
                  <paragraph>
                     <content styleCode="bold">General</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">This product is not suitable for multi-dose use. Following administration of the desired dose, any remaining suspension should be discarded.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Injection of methylprednisolone acetate may result in dermal and/or subdermal changes forming depressions in the skin at the injection site.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">In order to minimize the incidence of dermal and subdermal atrophy, care must be exercised not to exceed recommended doses in injections. Multiple small injections into the area of the lesion should be made whenever possible. The technique of intra-articular and intramuscular injection should include precautions against injection or leakage into the dermis. Injection into the deltoid muscle should be avoided because of a high incidence of subcutaneous atrophy.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">It is critical that, during administration of methylprednisolone acetate injectable suspension, appropriate technique be used and care taken to ensure proper placement of drug.</content>
                  </paragraph>
                  <paragraph>Rare instances of anaphylactoid reactions have occurred in patients receiving corticosteroid therapy (see
 
  <content styleCode="bold">
                        <linkHtml href="#LINK_057976f3-2b97-4390-9d11-47ba93b86d52">ADVERSE REACTIONS</linkHtml>
                     </content>).

 </paragraph>
                  <paragraph>Increased dosage of rapidly acting corticosteroids is indicated in patients on corticosteroid therapy subjected to any unusual stress before, during, and after the stressful situation.</paragraph>
                  <paragraph>Results from one multicenter, randomized, placebo-controlled study with methylprednisolone hemisuccinate, an IV corticosteroid, showed an increase in early (at 2 weeks) and late (at 6 months) mortality in patients with cranial trauma who were determined not to have other clear indications for corticosteroid treatment. High doses of systemic corticosteroids, including methylprednisolone acetate, should not be used for the treatment of traumatic brain injury.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Cardio-renal</content>
                  </paragraph>
                  <paragraph>Average and large doses of corticosteroids can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with synthetic derivatives when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion.</paragraph>
                  <paragraph>Literature reports suggest an apparent association between use of corticosteroids and left ventricular free wall rupture after a recent myocardial infarction; therefore, therapy with corticosteroids should be used with great caution in these patients.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Endocrine</content>
                  </paragraph>
                  <paragraph>Hypothalamic-pituitary adrenal (HPA) axis suppression. Cushing’s syndrome, and Hyperglycemia: Monitor patients for these conditions with chronic use.</paragraph>
                  <paragraph>Corticosteroids can produce reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Drug induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Infections</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">General</content>
                     </content>
                  </paragraph>
                  <paragraph>Persons who are on corticosteroids are more susceptible to infections than are healthy individuals. There may be decreased resistance and inability to localize infection when corticosteroids are used. Infections with any pathogen (viral, bacterial, fungal, protozoan, or helminthic) in any location of the body, may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents.</paragraph>
                  <paragraph>These infections may be mild, but can be severe and at times fatal. With increasing doses of corticosteroids, the rate of occurrence of infectious complications increases. Do not use intra-articularly, intrabursally, or for intratendinous administration for local effect in the presence of an acute infection. Corticosteroids may mask some signs of infection and new infections may appear during their use.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Fungal Infections</content>
                     </content>
                  </paragraph>
                  <paragraph>Corticosteroids may exacerbate systemic fungal infections and therefore should not be used in the presence of such infections unless they are needed to control drug interactions. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure (see
 
  <content styleCode="bold">
                        <linkHtml href="#LINK_cb64d219-4c1b-4230-aa26-3cb55f243c8c">CONTRAINDICATIONS</linkHtml>
                     </content>and
 
  <content styleCode="bold">
                        <linkHtml href="#LINK_3d6cff67-0c10-4ca9-a154-9f6ed9bf377f">PRECAUTIONS</linkHtml>:
  
   <linkHtml href="#LINK_65f2397e-bf80-4fe8-8dfa-2a992d3a5634">Drug Interactions</linkHtml>,
 
  </content>
                     <content styleCode="italics">Amphotericin B injection and potassium-depleting agents</content>).

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Special Pathogens</content>
                     </content>
                  </paragraph>
                  <paragraph>Latent disease may be activated or there may be an exacerbation of intercurrent infections due to pathogens, including those caused by
 
  <content styleCode="italics">Amoeba, Candida, Cryptococcus, Mycobacterium, Nocardia, Pneumocystis,</content>and
 
  <content styleCode="italics">Toxoplasma.</content>
                  </paragraph>
                  <paragraph>It is recommended that latent amebiasis or active amebiasis be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or in any patient with unexplained diarrhea.</paragraph>
                  <paragraph>Similarly, corticosteroids should be used with great care in patients with known or suspected
 
  <content styleCode="italics">Strongyloides</content>(threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to
 
  <content styleCode="italics">Strongyloides</content>hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

 </paragraph>
                  <paragraph>Corticosteroids should not be used in cerebral malaria. There is currently no evidence of benefit from steroids in this condition.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Tuberculosis</content>
                     </content>
                  </paragraph>
                  <paragraph>The use of corticosteroids in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.</paragraph>
                  <paragraph>If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary, as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Vaccinations</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered. However, the response to such vaccines cannot be predicted.</content>
                  </paragraph>
                  <paragraph>Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy (e.g., for Addison’s disease).</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Viral Infections</content>
                     </content>
                  </paragraph>
                  <paragraph>Chicken pox and measles can have a more serious or even fatal course in pediatric and adult patients on corticosteroids. In pediatric and adult patients who have not had these diseases, particular care should be taken to avoid exposure. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with immunoglobulin (IG) may be indicated (see the respective package inserts for complete VZIG and IG prescribing information). If chicken pox develops, treatment with antiviral agents should be considered.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Ophthalmic</content>
                  </paragraph>
                  <paragraph>Use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. The use of systemic corticosteroids is not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes. Corticosteroids should be used cautiously in patients with ocular herpes simplex because of corneal perforation. Corticosteroids should not be used in active ocular herpes simplex.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="LINK_3d6cff67-0c10-4ca9-a154-9f6ed9bf377f">
               <id root="01ca2f07-9c25-e418-e063-6294a90ac760"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20230731"/>
               <component>
                  <section ID="LINK_ead8bedb-d322-48f6-857b-47edfda91b76">
                     <id root="01ca2f07-9c26-e418-e063-6294a90ac760"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>This product, like many other corticosteroids, is sensitive to heat. Therefore, it should not be autoclaved when it is desirable to sterilize the exterior of the vial.</paragraph>
                        <paragraph>The lowest possible dose of corticosteroid should be used to control the condition under treatment. When reduction in dosage is possible, the reduction should be gradual.</paragraph>
                        <paragraph>Since complications of treatment with glucocorticosteroids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.</paragraph>
                        <paragraph>Karposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Cardio-renal</content>
                        </paragraph>
                        <paragraph>Caution is required in patients with systemic sclerosis because an increased incidence of scleroderma renal crisis has been observed with corticosteroids, including methylprednisolone.</paragraph>
                        <paragraph>As sodium retention with resultant edema and potassium loss may occur in patients receiving corticosteroids, these agents should be used with caution in patients with congestive heart failure or renal insufficiency.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Endocrine</content>
                        </paragraph>
                        <paragraph>Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted.</paragraph>
                        <paragraph>Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Gastrointestinal</content>
                        </paragraph>
                        <paragraph>Steroids should be used with caution in active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and nonspecific ulcerative colitis, since they may increase the risk of perforation.</paragraph>
                        <paragraph>Signs of peritoneal irritation following gastrointestinal perforation in patients receiving corticosteroids may be minimal or absent.</paragraph>
                        <paragraph>There is an enhanced effect due to decreased metabolism of corticosteroids in patients with cirrhosis.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Parenteral Administration</content>
                        </paragraph>
                        <paragraph>Intra-articularly injected corticosteroids may be systemically absorbed.</paragraph>
                        <paragraph>Appropriate examination of any joint fluid present is necessary to exclude a septic process.</paragraph>
                        <paragraph>A marked increase in pain accompanied by local swelling, further restriction of joint motion, fever, and malaise are suggestive of septic arthritis. If this complication occurs and diagnosis of sepsis is confirmed, appropriate antimicrobial therapy should be instituted.</paragraph>
                        <paragraph>Injection of a steroid into an infected site is to be avoided. Local injection of a steroid into a previously infected joint is not usually recommended.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Musculoskeletal</content>
                        </paragraph>
                        <paragraph>Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (e.g., decreasing absorption and increasing excretion) and inhibition of osteoblast function. This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to an inhibition of bone growth in pediatric patients and the development of osteoporosis at any age. Special consideration should be given to patients at increased risk of osteoporosis (i.e. postmenopausal women) before initiating corticosteroid therapy.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Neuro-psychiatric</content>
                        </paragraph>
                        <paragraph>An acute myopathy has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevation of creatine kinase may occur. Clinical improvement or recovery after stopping corticosteroids may require weeks to years.</paragraph>
                        <paragraph>Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Ophthalmic</content>
                        </paragraph>
                        <paragraph>Intraocular pressure may become elevated in some individuals. If steroid therapy is continued long-term, intraocular pressure should be monitored.</paragraph>
                        <paragraph>Corticosteroids should be used cautiously in patients with ocular herpes simplex for fear of corneal perforation.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Information for the Patient</content>
                        </paragraph>
                        <paragraph>Patients should be warned not to discontinue the use of corticosteroids abruptly or without medical supervision, to advise any medical attendants that they are taking corticosteroids and to seek medical advice at once should they develop a fever or other signs of infection.</paragraph>
                        <paragraph>Persons who are on corticosteroids should be warned to avoid exposure to chicken pox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_65f2397e-bf80-4fe8-8dfa-2a992d3a5634">
                     <id root="01ca2f07-9c27-e418-e063-6294a90ac760"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Aminoglutethimide</content>: Aminoglutethimide may lead to a loss of corticosteroid-induced adrenal suppression.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Amphotericin B injection and potassium-depleting agents:</content>When corticosteroids are administered concomitantly with potassium depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia. There have been cases reported in which concomitant use of amphotericin B and hydrocortisone was followed by cardiac enlargement and congestive heart failure.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Antibiotics</content>: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see
 
  <content styleCode="bold">
                              <linkHtml href="#LINK_3d6cff67-0c10-4ca9-a154-9f6ed9bf377f">PRECAUTIONS</linkHtml>:
  
   <linkHtml href="#LINK_65f2397e-bf80-4fe8-8dfa-2a992d3a5634">Drug Interactions</linkHtml>,
 
  </content>
                           <content styleCode="italics">Hepatic Enzyme Inhibitors</content>).

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Anticholinesterases:</content>Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Anticoagulants</content>,
 
  <content styleCode="italics">oral</content>: Co-administration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Antidiabetics:</content>Because corticosteroids may increase blood glucose concentration, dosage adjustments of antidiabetic agents may be required.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Antitubercular drugs:</content>Serum concentrations of isoniazid may be decreased.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cholestyramine:</content>Cholestyramine may increase the clearance of oral corticosteroids.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cyclosporine:</content>Increased activity of both cyclosporine and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Digitalis glycosides:</content>Patients on digitalis glycosides may be at risk of arrhythmias due to hypokalemia.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Estrogens, including oral contraceptives:</content>Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin):</content>Drugs which induce cytochrome P450 3A4 enzyme activity may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Enzyme Inhibitors (e.g., ketoconazole, macrolide antibiotics such as erythromycin and troleandomycin):</content>Drugs which inhibit cytochrome P450 3A4 have the potential to result in increased plasma concentrations of corticosteroids.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Ketoconazole</content>: Ketoconazole has been reported to significantly decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Nonsteroidal anti-inflammatory drugs (NSAIDs)</content>: Concomitant use of aspirin (or other nonsteroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin tests</content>: Corticosteroids may suppress reactions to skin tests.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Vaccines</content>: Patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. Routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued if possible (see
 
  <content styleCode="bold">
                              <linkHtml href="#LINK_86809099-c76f-4f42-8f43-de62e31b9218">WARNINGS</linkHtml>: Infections,
  
   <content styleCode="italics">Vaccinations</content>
                           </content>).

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_90444604-1368-49f2-82f8-67bbaa838fa5">
                     <id root="01ca2f07-9c28-e418-e063-6294a90ac760"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No adequate studies have been conducted in animals to determine whether corticosteroids have a potential for carcinogenesis or mutagenesis.</paragraph>
                        <paragraph>Steroids may increase or decrease motility and number of spermatozoa in some patients.</paragraph>
                        <paragraph>Corticosteroids have been shown to impair fertility in male rats.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_25844cc3-7047-4581-8d55-59d64028d94a">
                     <id root="01ca2f07-9c29-e418-e063-6294a90ac760"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy: Teratogenic Effects</title>
                     <text>
                        <paragraph>Corticosteroids have been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which corticosteroids have been given to pregnant mice, rats, and rabbits have yielded an increased incidence of cleft palate in the offspring. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_951cbbf8-1f80-4f9f-8ba2-b092e47074a0">
                     <id root="01ca2f07-9c2a-e418-e063-6294a90ac760"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Because of the potential for serious adverse reactions in nursing infants from corticosteroids, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_71dee26a-bab5-4ca6-9ec1-a8232e8bf330">
                     <id root="01ca2f07-9c2b-e418-e063-6294a90ac760"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>The efficacy and safety of corticosteroids in the pediatric population are based on the well-established course of effect of corticosteroids which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of nephritic syndrome (patients &gt; 2 years of age) and aggressive lymphomas and leukemias (patients &gt; 1 month of age). Other indications for pediatric use of corticosteroids (e.g., severe asthma and wheezing) are based on adequate and well-controlled clinical trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations.</paragraph>
                        <paragraph>The adverse effects of corticosteroids in pediatric patients are similar to those in adults (see
 
  <content styleCode="bold">
                              <linkHtml href="#LINK_057976f3-2b97-4390-9d11-47ba93b86d52">ADVERSE REACTIONS</linkHtml>
                           </content>). Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism, peptic ulcers, cataracts, and osteoporosis. Pediatric patients who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression (i.e. cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA axis function. The linear growth of pediatric patients treated with corticosteroids should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of treatment alternatives. In order to minimize the potential growth effects of corticosteroids, pediatric patients should be titrated to the lowest effective dose.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3f73bdcc-2802-457d-b0f6-fe3539146d9a">
                     <id root="01ca2f07-9c2c-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_057976f3-2b97-4390-9d11-47ba93b86d52">
               <id root="01ca2f07-9c2d-e418-e063-6294a90ac760"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions have been reported with methylprednisolone acetate or other corticosteroids:</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Allergic reactions</content>
                     </content>
                     <content styleCode="bold">:</content>Allergic or hypersensitivity reactions, anaphylactoid reaction, anaphylaxis, angioedema.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Blood and lymphatic system disorders:</content>
                     </content>Leukocytosis.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Cardiovascular</content>
                     </content>
                     <content styleCode="bold">:</content>Bradycardia, cardiac arrest, cardiac arrhythmias, cardiac enlargement, circulatory collapse, congestive heart failure, fat embolism, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture following recent myocardial infarction (see
 
  <content styleCode="bold">
                        <linkHtml href="#LINK_86809099-c76f-4f42-8f43-de62e31b9218">WARNINGS</linkHtml>
                     </content>), pulmonary edema, syncope, tachycardia, thromboembolism, thrombophlebitis, vasculitis.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Dermatologic</content>
                     </content>
                     <content styleCode="bold">:</content>Acne, allergic dermatitis, cutaneous and subcutaneous atrophy, dry scaly skin, ecchymoses and petechiae, edema, erythema, hyperpigmentation, hypopigmentation, impaired wound healing, increased sweating, rash, sterile abscess, striae, suppressed reactions to skin tests, thin fragile skin, thinning scalp hair, urticaria.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Endocrine</content>
                     </content>
                     <content styleCode="bold">:</content>Decreased carbohydrate and glucose tolerance, development of cushingoid state, glycosuria, hirsutism, hypertrichosis, increased requirements for insulin or oral hypoglycemic agents in diabetes, manifestations of latent diabetes mellitus, menstrual irregularities, secondary adrenocortical and pituitary unresponsiveness (particularly in times of stress, as in trauma, surgery, or illness), suppression of growth in pediatric patients.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Fluid and electrolyte disturbances</content>
                     </content>: Congestive heart failure in susceptible patients, fluid retention, hypokalemic alkalosis, potassium loss, sodium retention.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Gastrointestinal</content>
                     </content>: Abdominal distention, bowel/bladder dysfunction (after intrathecal administration), elevation in serum liver enzyme levels (usually reversible upon discontinuation), hepatomegaly, increased appetite, nausea, pancreatitis, peptic ulcer with possible subsequent perforation and hemorrhage, perforation of the small and large intestine (particularly in patients with inflammatory bowel disease), ulcerative esophagitis.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Metabolic</content>
                     </content>: Negative nitrogen balance due to protein catabolism.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Musculoskeletal</content>
                     </content>: Aseptic necrosis of femoral and humeral heads, calcinosis (following intra-articular or intra-lesional use), Charcot-like arthropathy, loss of muscle mass, muscle weakness, osteoporosis, pathologic fracture of long bones, postinjection flare (following intra-articular use), steroid myopathy, tendon rupture, vertebral compression fractures.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Neurologic/Psychiatric</content>
                     </content>: Convulsions, depression, emotional instability, euphoria, headache, increased intracranial pressure with papilledema (pseudotumor cerebri) usually following discontinuation of treatment, insomnia, mood swings, neuritis, neuropathy, paresthesia, personality changes, psychic disorders, vertigo.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Ophthalmic</content>
                     </content>: Exophthalmoses, glaucoma, increased intraocular pressure, posterior subcapsular cataracts.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Other</content>
                     </content>
                     <content styleCode="italics">:</content>Abnormal fat deposits, decreased resistance to infection, hiccups, increased or decreased motility and number of spermatozoa, injection site infections following non-sterile administration (see
 
  <content styleCode="bold">
                        <linkHtml href="#LINK_86809099-c76f-4f42-8f43-de62e31b9218">WARNINGS</linkHtml>
                     </content>), malaise, moon face, weight gain.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">The following adverse reactions have been reported with the following routes of administration:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Intrathecal/Epidural</content>
                     </content>: Arachnoiditis, bowel/bladder dysfunction, headache, meningitis, parapareisis/paraplegia, seizures, sensory disturbances.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Intranasal</content>
                     </content>: Allergic reactions, rhinitis, temporary/permanent visual impairment including blindness.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Ophthalmic</content>
                     </content>: Increased intraocular pressure, infection, ocular and periocular inflammation including allergic reactions, residue or slough at injection site, temporary/permanent visual impairment including blindness.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Miscellaneous injection sites</content>
                     </content>(scalp, tonsillar fauces, sphenopalatine ganglion): Blindness.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="LINK_fdf9a68e-e21c-452f-8573-81782900d973">
               <id root="01ca2f07-9c2e-e418-e063-6294a90ac760"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Treatment of acute overdosage is by supportive and symptomatic therapy. For chronic overdosage in the face of severe disease requiring continuous steroid therapy, the dosage of the corticosteroid may be reduced only temporarily, or alternate day treatment may be introduced.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="LINK_36cded2e-2c1e-44c2-a834-089b5dc8d613">
               <id root="01ca2f07-9c2f-e418-e063-6294a90ac760"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Because of possible physical incompatibilities, methylprednisolone acetate injectable suspension should not be diluted or mixed with other solutions.</content>
                  </paragraph>
                  <paragraph>The initial dosage of parenterally administered methylprednisolone acetate injectable suspension will vary from 4 mg to 120 mg, depending on the specific disease entity being treated. However, in certain overwhelming, acute, life-threatening situations, administration in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages.</paragraph>
                  <paragraph>
                     <content styleCode="italics">It Should Be Emphasized that Dosage Requirements Are Variable and Must Be Individualized on the Basis of the Disease Under Treatment and the Response of the Patient.</content>After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. Situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this latter situation, it may be necessary to increase the dosage of the corticosteroid for a period of time consistent with the patient’s condition. If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">A. Administration for Local Effect</content>
                  </paragraph>
                  <paragraph>Therapy with methylprednisolone acetate injectable suspension does not obviate the need for the conventional measures usually employed. Although this method of treatment will ameliorate symptoms, it is in no sense a cure and the hormone has no effect on the cause of the inflammation.</paragraph>
                  <paragraph>
                     <content styleCode="bold">1. Rheumatoid Arthritis and Osteoarthritis.</content>The dose for intra-articular administration depends upon the size of the joint and varies with the severity of the condition in the individual patient. In chronic cases, injections may be repeated at intervals ranging from one to five or more weeks, depending upon the degree of relief obtained from the initial injection. The doses in the following table are given as a general guide:

 </paragraph>
                  <table width="100%" border="0" cellspacing="0" cellpadding="0">
                     <col width="17px"/>
                     <col width="17px"/>
                     <col width="17px"/>
                     <tbody>
                        <tr>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>
                                 <content styleCode="italics">
                                    <content styleCode="bold">Size of</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">
                                    <content styleCode="bold">Joint</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>
                                 <content styleCode="italics">
                                    <content styleCode="bold">Examples</content>
                                 </content>
                              </paragraph>
                           </td>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>
                                 <content styleCode="italics">
                                    <content styleCode="bold">Range</content>
                                 </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics">
                                    <content styleCode="bold">of Dosage</content>
                                 </content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Large</paragraph>
                           </td>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Knees</paragraph>
                              <paragraph>Ankles</paragraph>
                              <paragraph>Shoulders</paragraph>
                           </td>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>20 mg to 80 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Medium</paragraph>
                           </td>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Elbows</paragraph>
                              <paragraph>Wrists</paragraph>
                           </td>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>10 mg to 40 mg</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Small</paragraph>
                           </td>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Metacarpophalangeal</paragraph>
                              <paragraph>Interphalangeal</paragraph>
                              <paragraph>Sternoclavicular</paragraph>
                              <paragraph>Acromioclavicular</paragraph>
                           </td>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>4 mg to 10 mg</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Procedure:</content>It is recommended that the anatomy of the joint involved be reviewed before attempting intra-articular injection. In order to obtain the full anti-inflammatory effect, it is important that the injection be made into the synovial space. Employing the same sterile technique as for a lumbar puncture, a sterile 20 to 24 gauge needle (on a dry syringe) is quickly inserted into the synovial cavity. Procaine infiltration is elective. The aspiration of only a few drops of joint fluid proves the joint space has been entered by the needle.
 
  <content styleCode="italics">The injection site for each joint is determined by that location where the synovial cavity is most superficial and most free of large vessels and nerves.</content>With the needle in place, the aspirating syringe is removed and replaced by a second syringe containing the desired amount of methylprednisolone acetate injectable suspension. The plunger is then pulled outward slightly to aspirate synovial fluid and to make sure the needle is still in the synovial space. After injection, the joint is moved gently a few times to aid mixing of the synovial fluid and the suspension. The site is covered with a small sterile dressing.

 </paragraph>
                  <paragraph>Suitable sites for intra-articular injection are the knee, ankle, wrist, elbow, shoulder, phalangeal, and hip joints. Since difficulty is not infrequently encountered in entering the hip joint, precautions should be taken to avoid any large blood vessels in the area. Joints not suitable for injection are those that are anatomically inaccessible such as the spinal joints and those like the sacroiliac joints that are devoid of synovial space. Treatment failures are most frequently the result of failure to enter the joint space. Little or no benefit follows injection into surrounding tissue. If failures occur when injections into the synovial spaces are certain, as determined by aspiration of fluid, repeated injections are usually futile.</paragraph>
                  <paragraph>If a local anesthetic is used prior to injection of methylprednisolone acetate injectable suspension, the anesthetic package insert should be read carefully and all the precautions observed.</paragraph>
                  <paragraph>
                     <content styleCode="bold">2. Bursitis</content>. The area around the injection site is prepared in a sterile way and a wheal at the site made with 1 percent procaine hydrochloride solution. A 20 to 24 gauge needle attached to a dry syringe is inserted into the bursa and the fluid aspirated. The needle is left in place and the aspirating syringe changed for a small syringe containing the desired dose. After injection, the needle is withdrawn and a small dressing applied.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">3. Miscellaneous: Ganglion, Tendinitis, Epicondylitis.</content>In the treatment of conditions such as tendinitis or tenosynovitis, care should be taken following application of a suitable antiseptic to the overlying skin to inject the suspension into the tendon sheath rather than into the substance of the tendon. The tendon may be readily palpated when placed on a stretch. When treating conditions such as epicondylitis, the area of greatest tenderness should be outlined carefully and the suspension infiltrated into the area. For ganglia of the tendon sheaths, the suspension is injected directly into the cyst. In many cases, a single injection causes a marked decrease in the size of the cystic tumor and may effect disappearance. The usual sterile precautions should be observed, of course, with each injection.

 </paragraph>
                  <paragraph>The dose in the treatment of the various conditions of the tendinous or bursal structures listed above varies with the condition being treated and ranges from 4 mg to 30 mg. In recurrent or chronic conditions, repeated injections may be necessary.</paragraph>
                  <paragraph>
                     <content styleCode="bold">4. Injections for Local Effect in Dermatologic Conditions</content>. Following cleansing with an appropriate antiseptic such as 70% alcohol, 20 mg to 60 mg is injected into the lesion. It may be necessary to distribute doses ranging from 20 mg to 40 mg by repeated local injections in the case of large lesions. Care should be taken to avoid injection of sufficient material to cause blanching since this may be followed by a small slough. One to four injections are usually employed, the intervals between injections varying with the type of lesion being treated and the duration of improvement produced by the initial injection.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">B. Administration for Systemic Effect</content>
                  </paragraph>
                  <paragraph>The intramuscular dosage will vary with the condition being treated. When employed as a temporary substitute for oral therapy, a single injection during each 24-hour period of a dose of the suspension equal to the total daily oral dose of methylprednisolone tablets, USP is usually sufficient. When a prolonged effect is desired, the weekly dose may be calculated by multiplying the daily oral dose by 7 and given as a single intramuscular injection.</paragraph>
                  <paragraph>In pediatric patients, the initial dose of methylprednisolone may vary depending on the specific disease entity being treated. Dosage must be individualized according to the severity of the disease and response of the patient. The recommended dosage may be reduced for pediatric patients, but dosage should be governed by the severity of the condition rather than by strict adherence to the ratio indicated by age or body weight.</paragraph>
                  <paragraph>In patients with the
 
  <content styleCode="bold">adrenogenital syndrome</content>, a single intramuscular injection of 40 mg every two weeks may be adequate. For maintenance of patients with
 
  <content styleCode="bold">rheumatoid arthritis</content>, the weekly intramuscular dose will vary from 40 mg to 120 mg. The usual dosage for patients with
 
  <content styleCode="bold">dermatologic lesions</content>benefited by systemic corticoid therapy is 40 mg to 120 mg of methylprednisolone acetate administered intramuscularly at weekly intervals for one to four weeks. In acute severe dermatitis due to poison ivy, relief may result within 8 to 12 hours following intramuscular administration of a single-dose of 80 mg to 120 mg. In chronic contact dermatitis, repeated injections at 5 to 10 day intervals may be necessary. In seborrheic dermatitis, a weekly dose of 80 mg may be adequate to control the condition.

 </paragraph>
                  <paragraph>Following intramuscular administration of 80 mg to 120 mg to asthmatic patients, relief may result within 6 to 48 hours and persist for several days to two weeks.</paragraph>
                  <paragraph>If signs of stress are associated with the condition being treated, the dosage of the suspension should be increased. If a rapid hormonal effect of maximum intensity is required, the intravenous administration of highly soluble methylprednisolone sodium succinate is indicated.</paragraph>
                  <paragraph>For the purpose of comparison, the following is the equivalent milligram dose of the various glucocorticoids:</paragraph>
                  <table width="100%" border="1" cellspacing="0" cellpadding="0">
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Cortisone, 25</paragraph>
                           </td>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Triamcinolone, 4</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Hydrocortisone, 20</paragraph>
                           </td>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Paramethasone, 2</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Prednisolone, 5</paragraph>
                           </td>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Betamethasone, 0.75</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Prednisone, 5</paragraph>
                           </td>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Dexamethasone, 0.75</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <paragraph>Methylprednisolone, 4</paragraph>
                           </td>
                           <td styleCode="     Botrule          Toprule         Lrule          Rrule     ">
                              <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="LINK_b95a0ea7-ca7d-47a0-9d15-cd4ca7caef99">
               <id root="01ccd14b-1bb3-a616-e063-6394a90aa42f"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Methylprednisolone Acetate Injectable Suspension, USP is supplied as a white to off-white homogenous suspension in single-dose vial available in the following strength and package size:</paragraph>
                  <paragraph>
                     <content styleCode="bold">80 mg/mL (1 mL)</content>
                  </paragraph>
                  <paragraph>Single vial in a carton: NDC 70121-1574-1</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>This product’s label may have been updated. For current full prescribing information, please visit www.amneal.com.</paragraph>
                  <paragraph>Manufactured by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Amneal Pharmaceuticals Pvt. Ltd.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Parenteral Unit</content>
                  </paragraph>
                  <paragraph>Ahmedabad 382213, INDIA</paragraph>
                  <paragraph>
                     <br/>
Distributed by:
 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Amneal</content>
                     <content styleCode="bold">Pharmaceuticals LLC</content>
                  </paragraph>
                  <paragraph>Bridgewater, NJ 08807</paragraph>
                  <paragraph>Rev. 07-2021-05</paragraph>
                  <paragraph/>
                  <paragraph>Distributed by:
  <br/>
                     <content styleCode="bold">Advanced Rx Pharmacy of Tennessee, LLC</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="e8ec904c-dc9b-423b-a953-d9f32bf6b4a8">
               <id root="01ca2f07-9c31-e418-e063-6294a90ac760"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Lidocaine HCl Injection, USP</content>
                  </paragraph>
                  <paragraph>For Infiltration and Nerve Block Including Caudal and Epidural Use.</paragraph>
                  <paragraph>Preservative-Free</paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="fa3a270a-1a49-4094-992a-6cdfb17b6896">
               <id root="01ca2f07-9c32-e418-e063-6294a90ac760"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Lidocaine hydrochloride injection, USP is sterile, nonpyrogenic, aqueous solution that contains a local anesthetic agent and is administered parenterally by injection. See
 
  <content styleCode="bold">
                        <linkHtml href="#Section_3">INDICATIONS AND USAGE</linkHtml>
                     </content>section for specific uses. 
  <br/>
                     <br/>  Lidocaine hydrochloride injection, USP contains lidocaine hydrochloride, which is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, monohydrochloride and has the molecular weight 270.8. Lidocaine hydrochloride (C
 
  <sub>14</sub>H
 
  <sub>22</sub>N
 
  <sub>2</sub>O • HCl) has the following structural formula:

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM3"/>
                  </paragraph>
                  <paragraph>Lidocaine hydrochloride injection, USP is a sterile, nonpyrogenic, isotonic solution containing sodium chloride. The pH of the solution is adjusted to approximately 6.5 (5.0 to 7.0) with sodium hydroxide and/or hydrochloric acid.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>Lidocaine Hydrochloride Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="dyu01-0004-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="01ca2f07-9c33-e418-e063-6294a90ac760"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20230731"/>
               <component>
                  <section ID="Section_2.1">
                     <id root="01ca2f07-9c34-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Mechanism of Action</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>Lidocaine hydrochloride stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses thereby effecting local anesthetic action.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="01ca2f07-9c35-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Hemodynamics</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>Excessive blood levels may cause changes in cardiac output, total peripheral resistance, and mean arterial pressure. With central neural blockade these changes may be attributable to block of autonomic fibers, a direct depressant effect of the local anesthetic agent on various components of the cardiovascular system, and/or the beta-adrenergic receptor stimulating action of epinephrine when present. The net effect is normally a modest hypotension when the recommended dosages are not exceeded.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="01ca2f07-9c36-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Pharmacokinetics and Metabolism</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>Information derived from diverse formulations, concentrations and usages reveals that lidocaine hydrochloride is completely absorbed following parenteral administration, its rate of absorption depending, for example, upon various factors such as the site of administration and the presence or absence of a vasoconstrictor agent. Except for intravascular administration, the highest blood levels are obtained following intercostal nerve block and the lowest after subcutaneous administration. 
  <br/>
                           <br/>  The plasma binding of lidocaine hydrochloride is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 mcg of free base per mL 60 to 80 percent of lidocaine hydrochloride is protein bound. Binding is also dependent on the plasma concentration of the alpha-1-acid glycoprotein. 
  <br/>
                           <br/>  Lidocaine hydrochloride crosses the blood-brain and placental barriers, presumably by passive diffusion. 
  <br/>
                           <br/>  Lidocaine hydrochloride is metabolized rapidly by the liver, and metabolites and unchanged drug are excreted by the kidneys. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation. N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethylglycinexylidide and glycinexylidide. The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of lidocaine hydrochloride. Approximately 90% of lidocaine hydrochloride administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged. The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline. 
  <br/>
                           <br/>  The elimination half-life of lidocaine hydrochloride following an intravenous bolus injection is typically 1.5 to 2 hours. Because of the rapid rate at which lidocaine hydrochloride is metabolized, any condition that affects liver function may alter lidocaine hydrochloride kinetics. The half-life may be prolonged two-fold or more in patients with liver dysfunction. Renal dysfunction does not affect lidocaine hydrochloride kinetics but may increase the accumulation of metabolites. 
  <br/>
                           <br/>  Factors such as acidosis and the use of CNS stimulants and depressants affect the CNS levels of lidocaine hydrochloride required to produce overt systemic effects. Objective adverse manifestations become increasingly apparent with increasing venous plasma levels above 6 mcg free base per mL. In the rhesus monkey arterial blood levels of 18 to 21 mcg/mL have been shown to be threshold for convulsive activity.
 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="01ca2f07-9c37-e418-e063-6294a90ac760"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <br/>
                  <paragraph>Lidocaine hydrochloride injection is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="01ca2f07-9c38-e418-e063-6294a90ac760"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <br/>
                  <paragraph>Lidocaine hydrochloride is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="01ca2f07-9c39-e418-e063-6294a90ac760"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <br/>
                  <paragraph>LIDOCAINE HYDROCHLORIDE INJECTION FOR INFILTRATION AND NERVE BLOCK SHOULD BE EMPLOYED ONLY BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES THAT MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED AND THEN ONLY AFTER ENSURING THE
 
  <content styleCode="italics">IMMEDIATE</content>AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY EQUIPMENT AND THE PERSONNEL NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES (see also
 
  <content styleCode="bold">
                        <content styleCode="bold">
                           <content styleCode="bold">
                              <linkHtml href="#Section_7">ADVERSE REACTIONS</linkHtml>
                           </content>
                        </content>
                     </content>and
 
  <content styleCode="bold">
                        <content styleCode="bold">
                           <linkHtml href="#Section_6">PRECAUTIONS</linkHtml>
                        </content>
                     </content>). DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF ACIDOSIS, CARDIAC ARREST AND, POSSIBLY, DEATH. 
  <br/>
                     <content styleCode="bold">
                        <content styleCode="italics">
                           <br/>  Methemoglobinemia 
    <br/>
                        </content>
                     </content>
                     <br/>  Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. 
  <br/>
                     <br/>  Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue lidocaine hydrochloride and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. 
  <br/>
                     <br/>  Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of chondrolysis in patients receiving such infusions. The majority of reported cases of chondrolysis have involved the shoulder joint; cases of gleno-humeral chondrolysis have been described in pediatric and adult patients following intra-articular infusions of local anesthetics with and without epinephrine for periods of 48 to 72 hours. There is insufficient information to determine whether shorter infusion periods are not associated with these findings. The time of onset of symptoms, such as joint pain, stiffness and loss of motion can be variable, but may begin as early as the 2
 
  <sup>nd</sup>month after surgery. Currently, there is no effective treatment for chondrolysis; patients who experienced chondrolysis have required additional diagnostic and therapeutic procedures and some required arthroplasty or shoulder replacement. 
  <br/>
                     <br/>  To avoid intravascular injection, aspiration should be performed before the local anesthetic solution is injected. The needle must be repositioned until no return of blood can be elicited by aspiration. Note, however, that the absence of blood in the syringe does not guarantee that intravascular injection has been avoided. 
  <br/>
                     <br/>  Anaphylactic reactions may occur following administration of lidocaine hydrochloride (see
 
  <content styleCode="bold">
                        <linkHtml href="#Section_7">ADVERSE REACTIONS</linkHtml>
                     </content>). 
  <br/>
                     <br/>  In the case of severe reaction, discontinue the use of the drug.

 </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="01ca2f07-9c3a-e418-e063-6294a90ac760"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20230731"/>
               <component>
                  <section ID="Section_6.1">
                     <id root="01ca2f07-9c3b-e418-e063-6294a90ac760"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">General</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>The safety and effectiveness of lidocaine hydrochloride depend on proper dosage, correct technique, adequate precautions, and readiness for emergencies. Standard textbooks should be consulted for specific techniques and precautions for various regional anesthetic procedures. 
  <br/>
                           <br/>  Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use (see
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#Section_5">WARNINGS</linkHtml>
                              </content>
                           </content>and
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#Section_7">ADVERSE REACTIONS</linkHtml>
                              </content>
                           </content>). The lowest dosage that results in effective anesthesia should be used to avoid high plasma levels and serious adverse effects. Syringe aspirations should also be performed before and during each supplemental injection when using indwelling catheter techniques. During the administration of epidural anesthesia, it is recommended that a test dose be administered initially and that the patient be monitored for central nervous system toxicity and cardiovascular toxicity, as well as for signs of unintended intrathecal administration, before proceeding. When clinical conditions permit, consideration should be given to employing local anesthetic solutions that contain epinephrine for the test dose because circulatory changes compatible with epinephrine may also serve as a warning sign of unintended intravascular injection. An intravascular injection is still possible even if aspirations for blood are negative. Repeated doses of lidocaine hydrochloride may cause significant increases in blood levels with each repeated dose because of slow accumulation of the drug or its metabolites. Tolerance to elevated blood levels varies with the status of the patient. Debilitated, elderly patients, acutely ill patients, and children should be given reduced doses commensurate with their age and physical condition. Lidocaine hydrochloride should also be used with caution in patients with severe shock or heart block. 
  <br/>
                           <br/>  Lumbar and caudal epidural anesthesia should be used with extreme caution in persons with the following conditions: existing neurological disease, spinal deformities, septicemia, and severe hypertension. 
  <br/>
                           <br/>  Local anesthetic solutions containing a vasoconstrictor should be used cautiously and in carefully circumscribed quantities in areas of the body supplied by end arteries or having otherwise compromised blood supply. Patients with peripheral vascular disease and those with hypertensive vascular disease may exhibit exaggerated vasoconstrictor response. Ischemic injury or necrosis may result. Preparations containing a vasoconstrictor should be used with caution in patients during or following the administration of potent general anesthetic agents, since cardiac arrhythmias may occur under such conditions. 
  <br/>
                           <br/>  Careful and constant monitoring of cardiovascular and respiratory (adequacy of ventilation) vital signs and the patient’s state of consciousness should be accomplished after each local anesthetic injection. It should be kept in mind at such times that restlessness, anxiety, tinnitus, dizziness, blurred vision, tremors, depression or drowsiness may be early warning signs of central nervous system toxicity. 
  <br/>
                           <br/>  Since amide-type local anesthetics are metabolized by the liver, lidocaine hydrochloride injection should be used with caution in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at greater risk of developing toxic plasma concentrations. Lidocaine hydrochloride injection should also be used with caution in patients with impaired cardiovascular function since they may be less able to compensate for functional changes associated with the prolongation of A-V conduction produced by these drugs. 
  <br/>
                           <br/>  Many drugs used during the conduct of anesthesia are considered potential triggering agents for familial malignant hyperthermia. Since it is not known whether amide-type local anesthetics may trigger this reaction and since the need for supplemental general anesthesia cannot be predicted in advance, it is suggested that a standard protocol for the management of malignant hyperthermia should be available. Early unexplained signs of tachycardia, tachypnea, labile blood pressure and metabolic acidosis may precede temperature elevation. Successful outcome is dependent on early diagnosis, prompt discontinuance of the suspect triggering agent(s) and institution of treatment, including oxygen therapy, indicated supportive measures and dantrolene (consult dantrolene sodium intravenous package insert before using). 
  <br/>
                           <br/>  Proper tourniquet technique, as described in publications and standard textbooks, is essential in the performance of intravenous regional anesthesia. Solutions containing epinephrine or other vasoconstrictors should not be used for this technique. 
  <br/>
                           <br/>  Lidocaine hydrochloride should be used with caution in persons with known drug sensitivities. Patients allergic to para-aminobenzoic acid derivatives (procaine, tetracaine, benzocaine, etc.) have not shown cross-sensitivity to lidocaine hydrochloride.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.12">
                     <id root="01ca2f07-9c3c-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Use in the Head and Neck Area</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>Small doses of local anesthetics injected into the head and neck area, including retrobulbar, dental and stellate ganglion blocks, may produce adverse reactions similar to systemic toxicity seen with unintentional intravascular injections of larger doses. Confusion, convulsions, respiratory depression and/or respiratory arrest, and cardiovascular stimulation or depression have been reported. These reactions may be due to intra-arterial injection of the local anesthetic with retrograde flow to the cerebral circulation. Patients receiving these blocks should have their circulation and respiration monitored and be constantly observed. Resuscitative equipment and personnel for treating adverse reactions should be immediately available. Dosage recommendations should not be exceeded (see
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>
                              </content>
                           </content>).

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.2">
                     <id root="01ca2f07-9c3d-e418-e063-6294a90ac760"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Information for Patients</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>When appropriate, patients should be informed in advance that they may experience temporary loss of sensation and motor activity, usually in the lower half of the body, following proper administration of epidural anesthesia. 
  <br/>
                           <br/>  Inform patients that use of local anesthetics may cause methemoglobinemia, a serious condition that must be treated promptly. Advise patients or caregivers to seek immediate medical attention if they or someone in their care experience the following signs or symptoms: pale, gray, or blue colored skin (cyanosis); headache; rapid heart rate; shortness of breath; lightheadedness; or fatigue.
 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.4">
                     <id root="01ca2f07-9c3e-e418-e063-6294a90ac760"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Clinically Significant Drug Interactions</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. 
  <br/>
                           <br/>  Phenothiazines and butyrophenones may reduce or reverse the pressor effect of epinephrine. 
  <br/>
                           <br/>  Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful patient monitoring is essential. 
  <br/>
                           <br/>  Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents.
 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.5">
                     <id root="01ca2f07-9c3f-e418-e063-6294a90ac760"/>
                     <code code="34074-5" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG &amp; OR LABORATORY TEST INTERACTIONS SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Drug/Laboratory Test Interactions</content>
                        </content>
                     </title>
                     <text>
                        <paragraph>The intramuscular injection of lidocaine hydrochloride may result in an increase in creatine phosphokinase levels. Thus, the use of this enzyme determination, without isoenzyme separation, as a diagnostic test for the presence of acute myocardial infarction may be compromised by the intramuscular injection of lidocaine hydrochloride. 
  <br/>
                           <br/>  Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics:
 </paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>Examples of Drugs Associated with Methemoglobinemia:</caption>
                           <col width="35.68%"/>
                           <col width="64.32%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="center" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Class</content>
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">Examples</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Nitrates/Nitrites 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">nitric oxide, nitroglycerin, nitroprusside, nitrous oxide 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Local anesthetics 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Antineoplastic agents 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Antibiotics 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Antimalarials 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">chloroquine, primaquine 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="middle">Anticonvulsants 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">Phenobarbital, phenytoin, sodium valproate 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="middle">Other drugs 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="middle">acetaminophen, metoclopramide, quinine, sulfasalazine 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.6">
                     <id root="01ca2f07-9c40-e418-e063-6294a90ac760"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>Studies of lidocaine hydrochloride in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility have not been conducted.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.7">
                     <id root="01ca2f07-9c41-e418-e063-6294a90ac760"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">Pregnancy</content>
                     </title>
                     <effectiveTime value="20230731"/>
                     <component>
                        <section ID="Section_6.7.1">
                           <id root="01ca2f07-9c42-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>Teratogenic Effects</title>
                           <text>
                              <paragraph>Reproduction studies have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine hydrochloride. There are, however, no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response. General consideration should be given to this fact before administering lidocaine hydrochloride to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place.</paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.8">
                     <id root="01ca2f07-9c43-e418-e063-6294a90ac760"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Labor and Delivery</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>Local anesthetics rapidly cross the placenta and when used for epidural, paracervical, pudendal or caudal block anesthesia, can cause varying degrees of maternal, fetal and neonatal toxicity (see
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <content styleCode="bold">
                                    <content styleCode="bold">
                                       <content styleCode="bold">
                                          <content styleCode="bold">
                                             <content styleCode="bold">
                                                <linkHtml href="#Section_2">CLINICAL PHARMACOLOGY</linkHtml>
                                             </content>,
      
       </content>
                                       </content>
                                       <content styleCode="italics">
                                          <content styleCode="bold">
                                             <linkHtml href="#Section_2.3">Pharmacokinetics and Metabolism</linkHtml>
                                          </content>
                                       </content>
                                    </content>
                                 </content>
                              </content>
                           </content>). The potential for toxicity depends upon the procedure performed, the type and amount of drug used, and the technique of drug administration. Adverse reactions in the parturient, fetus and neonate involve alterations of the central nervous system, peripheral vascular tone and cardiac function. 
  <br/>
                           <br/>  Maternal hypotension has resulted from regional anesthesia. Local anesthetics produce vasodilation by blocking sympathetic nerves. Elevating the patient’s legs and positioning her on her left side will help prevent decreases in blood pressure. 
  <br/>
                           <br/>  The fetal heart rate also should be monitored continuously, and electronic fetal monitoring is highly advisable. 
  <br/>
                           <br/>  Epidural, spinal, paracervical, or pudendal anesthesia may alter the forces of parturition through changes in uterine contractility or maternal expulsive efforts. In one study, paracervical block anesthesia was associated with a decrease in the mean duration of first stage labor and facilitation of cervical dilation. However, spinal and epidural anesthesia have also been reported to prolong the second stage of labor by removing the parturient’s reflex urge to bear down or by interfering with motor function. The use of obstetrical anesthesia may increase the need for forceps assistance. 
  <br/>
                           <br/>  The use of some local anesthetic drug products during labor and delivery may be followed by diminished muscle strength and tone for the first day or two of life. The long-term significance of these observations is unknown. Fetal bradycardia may occur in 20 to 30 percent of patients receiving paracervical nerve block anesthesia with the amide-type local anesthetics and may be associated with fetal acidosis. Fetal heart rate should always be monitored during paracervical anesthesia. The physician should weigh the possible advantages against risks when considering a paracervical block in prematurity, toxemia of pregnancy, and fetal distress. Careful adherence to recommended dosage is of the utmost importance in obstetrical paracervical block. Failure to achieve adequate analgesia with recommended doses should arouse suspicion of intravascular or fetal intracranial injection. Cases compatible with unintended fetal intracranial injection of local anesthetic solution have been reported following intended paracervical or pudendal block or both. Babies so affected present with unexplained neonatal depression at birth, which correlates with high local anesthetic serum levels, and often manifest seizures within six hours. Prompt use of supportive measures combined with forced urinary excretion of the local anesthetic has been used successfully to manage this complication. 
  <br/>
                           <br/>  Case reports of maternal convulsions and cardiovascular collapse following use of some local anesthetics for paracervical block in early pregnancy (as anesthesia for elective abortion) suggest that systemic absorption under these circumstances may be rapid. The recommended maximum dose of each drug should not be exceeded. Injection should be made slowly and with frequent aspiration. Allow a 5-minute interval between sides.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.9">
                     <id root="01ca2f07-9c44-e418-e063-6294a90ac760"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Nursing Mothers</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when lidocaine hydrochloride is administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_6.10">
                     <id root="01ca2f07-9c45-e418-e063-6294a90ac760"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Pediatric Use</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>Dosages in children should be reduced, commensurate with age, body weight and physical condition, see
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>
                              </content>.
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="01ca2f07-9c46-e418-e063-6294a90ac760"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <effectiveTime value="20230731"/>
               <component>
                  <section ID="Section_7.1">
                     <id root="01ca2f07-9c47-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Systemic</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>Adverse experiences following the administration of lidocaine hydrochloride are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption or inadvertent intravascular injection, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported:</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                     <component>
                        <section ID="Section_7.1.1">
                           <id root="01ca2f07-9c48-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Central Nervous System</content>
                              </content>
                           </title>
                           <text>
                              <br/>
                              <paragraph>CNS manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest.</paragraph>
                              <paragraph>Drowsiness following the administration of lidocaine hydrochloride is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption.</paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_7.1.2">
                           <id root="01ca2f07-9c49-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Cardiovascular System</content>
                              </content>
                           </title>
                           <text>
                              <br/>
                              <paragraph>Cardiovascular manifestations are usually depressant and are characterized by bradycardia, hypotension, and cardiovascular collapse, which may lead to cardiac arrest.</paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_7.1.3">
                           <id root="01ca2f07-9c4a-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Allergic</content>
                              </content>
                           </title>
                           <text>
                              <paragraph>Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions. Allergic reactions may occur as a result of sensitivity to local anesthetic agents. Allergic reactions, including anaphylactic reactions, may occur as a result of sensitivity to lidocaine, but are infrequent. If allergic reactions do occur, they should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value. 
  <br/>
                                 <br/>  There have been no reports of cross sensitivity between lidocaine hydrochloride and procainamide or between lidocaine hydrochloride and quinidine.
 </paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_7.1.4">
                           <id root="01ca2f07-9c4b-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Neurologic</content>
                              </content>
                           </title>
                           <text>
                              <br/>
                              <paragraph>The incidences of adverse reactions associated with the use of local anesthetics may be related to the total dose of local anesthetic administered and are also dependent upon the particular drug used, the route of administration and the physical status of the patient. In a prospective review of 10,440 patients who received lidocaine hydrochloride for spinal anesthesia, the incidences of adverse reactions were reported to be about 3 percent each for positional headaches, hypotension and backache; 2 percent for shivering; and less than 1 percent each for peripheral nerve symptoms, nausea, respiratory inadequacy and double vision. Many of these observations may be related to local anesthetic techniques, with or without a contribution from the local anesthetic. 
  <br/>
                                 <br/>  In the practice of caudal or lumbar epidural block, occasional unintentional penetration of the subarachnoid space by the catheter may occur. Subsequent adverse effects may depend partially on the amount of drug administered subdurally. These may include spinal block of varying magnitude (including total spinal block), hypotension secondary to spinal block, loss of bladder and bowel control, and loss of perineal sensation and sexual function. Persistent motor, sensory and/or autonomic (sphincter control) deficit of some lower spinal segments with slow recovery (several months) or incomplete recovery have been reported in rare instances when caudal or lumbar epidural block has been attempted. Backache and headache have also been noted following use of these anesthetic procedures. 
  <br/>
                                 <br/>  There have been reported cases of permanent injury to extraocular muscles requiring surgical repair following retrobulbar administration.
 </paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Section_7.1.5">
                           <id root="01ca2f07-9c4c-e418-e063-6294a90ac760"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="bold">
                                 <content styleCode="italics">Hematologic</content>
                              </content>
                           </title>
                           <text>
                              <paragraph>Methemoglobinemia.</paragraph>
                           </text>
                           <effectiveTime value="20230731"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_9">
               <id root="01ca2f07-9c4d-e418-e063-6294a90ac760"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <br/>
                  <paragraph>Acute emergencies from local anesthetics are generally related to high plasma levels encountered during therapeutic use of local anesthetics or to unintended subarachnoid injection of local anesthetic solution (see
 
  <content styleCode="bold">
                        <content styleCode="bold">
                           <content styleCode="bold">
                              <linkHtml href="#Section_7">ADVERSE REACTIONS</linkHtml>
                           </content>
                        </content>,
  
   <content styleCode="bold">
                           <linkHtml href="#Section_5">WARNINGS</linkHtml>
                        </content>,
 
  </content>and
 
  <content styleCode="bold">
                        <content styleCode="bold">
                           <content styleCode="bold">
                              <content styleCode="bold">
                                 <content styleCode="bold">
                                    <content styleCode="bold">
                                       <content styleCode="bold">
                                          <content styleCode="bold">
                                             <content styleCode="bold">
                                                <linkHtml href="#Section_6">PRECAUTIONS</linkHtml>
                                             </content>
                                          </content>
                                       </content>
                                    </content>
                                 </content>).
    
     </content>
                           </content>
                        </content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
               <component>
                  <section ID="Section_9.1">
                     <id root="01ca2f07-9c4e-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Management of Local Anesthetic Emergencies</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>The first consideration is prevention, best accomplished by careful and constant monitoring of cardiovascular and respiratory vital signs and the patient’s state of consciousness after each local anesthetic injection. At the first sign of change, oxygen should be administered. 
  <br/>
                           <br/>  The first step in the management of convulsions, as well as underventilation or apnea due to unintended subarachnoid injection of drug solution, consists of immediate attention to the maintenance of a patent airway and assisted or controlled ventilation with oxygen and a delivery system capable of permitting immediate positive airway pressure by mask. Immediately after the institution of these ventilatory measures, the adequacy of the circulation should be evaluated, keeping in mind that drugs used to treat convulsions sometimes depress the circulation when administered intravenously. Should convulsions persist despite adequate respiratory support, and if the status of the circulation permits, small increments of an ultra-short acting barbiturate (such as thiopental or thiamylal) or a benzodiazepine (such as diazepam) may be administered intravenously. The clinician should be familiar, prior to the use of local anesthetics, with these anticonvulsant drugs. Supportive treatment of circulatory depression may require administration of intravenous fluids and, when appropriate, a vasopressor as directed by the clinical situation (e.g., ephedrine). 
  <br/>
                           <br/>  If not treated immediately, both convulsions and cardiovascular depression can result in hypoxia, acidosis, bradycardia, arrhythmias and cardiac arrest. Underventilation or apnea due to unintentional subarachnoid injection of local anesthetic solution may produce these same signs and also lead to cardiac arrest if ventilatory support is not instituted. If cardiac arrest should occur, standard cardiopulmonary resuscitative measures should be instituted. 
  <br/>
                           <br/>  Endotracheal intubation, employing drugs and techniques familiar to the clinician, may be indicated, after initial administration of oxygen by mask, if difficulty is encountered in the maintenance of a patent airway or if prolonged ventilatory support (assisted or controlled) is indicated. 
  <br/>
                           <br/>  Dialysis is of negligible value in the treatment of acute overdosage with lidocaine hydrochloride. 
  <br/>
                           <br/>  The oral LD
 
  <sub>50</sub>of lidocaine hydrochloride in non-fasted female rats is 459 (346 to 773) mg/kg (as the salt) and 214 (159 to 324) mg/kg (as the salt) in fasted female rats.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="01ca2f07-9c4f-e418-e063-6294a90ac760"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <br/>
                  <paragraph>Table 1 (Recommended Dosages) summarizes the recommended volumes and concentrations of lidocaine hydrochloride injection for various types of anesthetic procedures. The dosages suggested in this table are for normal healthy adults and refer to the use of epinephrine-free solutions. When larger volumes are required, only solutions containing epinephrine should be used except in those cases where vasopressor drugs may be contraindicated. 
  <br/>
                     <br/>  There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. Lidocaine hydrochloride injection is not approved for this use (see
 
  <content styleCode="bold">
                        <content styleCode="bold">
                           <linkHtml href="#Section_5">WARNINGS</linkHtml>
                        </content>
                     </content>and
 
  <content styleCode="bold">
                        <content styleCode="bold">
                           <linkHtml href="#Section_10">DOSAGE AND ADMINISTRATION</linkHtml>
                        </content>
                     </content>). 
  <br/>
                     <br/>  These recommended doses serve only as a guide to the amount of anesthetic required for most routine procedures. The actual volumes and concentrations to be used depend on a number of factors such as type and extent of surgical procedure, depth of anesthesia and degree of muscular relaxation required, duration of anesthesia required, and the physical condition of the patient. In all cases the lowest concentration and smallest dose that will produce the desired result should be given. Dosages should be reduced for children and for the elderly and debilitated patients and patients with cardiac and/or liver disease. 
  <br/>
                     <br/>  The onset of anesthesia, the duration of anesthesia and the degree of muscular relaxation are proportional to the volume and concentration (i.e., total dose) of local anesthetic used. Thus, an increase in volume and concentration of lidocaine hydrochloride injection will decrease the onset of anesthesia, prolong the duration of anesthesia, provide a greater degree of muscular relaxation and increase the segmental spread of anesthesia. However, increasing the volume and concentration of lidocaine hydrochloride injection may result in a more profound fall in blood pressure when used in epidural anesthesia. Although the incidence of side effects with lidocaine hydrochloride is quite low, caution should be exercised when employing large volumes and concentrations, since the incidence of side effects is directly proportional to the total dose of local anesthetic agent injected.

 </paragraph>
               </text>
               <effectiveTime value="20230731"/>
               <component>
                  <section ID="Section_10.1">
                     <id root="01ca2f07-9c50-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Epidural Anesthesia</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>For epidural anesthesia the following dosage form of lidocaine hydrochloride injection is recommended: 
  <br/>
                           <br/>  1% without epinephrine 30 mL single dose vials 
  <br/>
                           <br/>  Although this solution is intended specifically for epidural anesthesia, it may also be used for infiltration and peripheral nerve block, provided it is employed as a single dose unit. 
  <br/>
                           <br/>  This solution contains no bacteriostatic agent. 
  <br/>
                           <br/>  In epidural anesthesia, the dosage varies with the number of dermatomes to be anesthetized (generally 2 to 3 mL of the indicated concentration per dermatome).
 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_10.2">
                     <id root="01ca2f07-9c51-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Caudal and Lumbar Epidural Block</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>As a precaution against the adverse experience sometimes observed following unintentional penetration of the subarachnoid space, a test dose such as 2 to 3 mL of 1.5% lidocaine hydrochloride should be administered at least 5 minutes prior to injecting the total volume required for a lumbar or caudal epidural block. The test dose should be repeated if the patient is moved in a manner that may have displaced the catheter. Epinephrine, if contained in the test dose (10 to 15 mcg have been suggested), may serve as a warning of unintentional intravascular injection. If injected into a blood vessel, this amount of epinephrine is likely to produce a transient “epinephrine response” within 45 seconds, consisting of an increase in heart rate and systolic blood pressure, circumoral pallor, palpitations and nervousness in the unsedated patient. The sedated patient may exhibit only a pulse rate increase of 20 or more beats per minute for 15 or more seconds. Patients on beta blockers may not manifest changes in heart rate, but blood pressure monitoring can detect an evanescent rise in systolic blood pressure. Adequate time should be allowed for onset of anesthesia after administration of each test dose. The rapid injection of a large volume of lidocaine hydrochloride injection through the catheter should be avoided, and, when feasible, fractional doses should be administered. 
  <br/>
                           <br/>  In the event of the known injection of a large volume of local anesthetic solution into the subarachnoid space, after suitable resuscitation and if the catheter is in place, consider attempting the recovery of drug by draining a moderate amount of cerebrospinal fluid (such as 10 mL) through the epidural catheter.
 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_17">
               <id root="01ca2f07-9c52-e418-e063-6294a90ac760"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>MAXIMUM RECOMMENDED DOSAGES</title>
               <effectiveTime value="20230731"/>
               <component>
                  <section ID="Unclassified_Section_17.1">
                     <id root="01ca2f07-9c53-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Adults</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>For normal healthy adults, the maximum individual dose should not exceed 4.5 mg/kg (2 mg/lb) of body weight, and in general it is recom mended that the max i m um t otal dose does not exceed 300 mg. For continuous epidural or caudal anesthesia, the maximum recommended dosage should not be administered at intervals of less than 90 minutes. When continuous lumbar or caudal epidural anesthesia is used for non-obstetrical procedures, more drug may be administered if required to produce adequate anesthesia. 
  <br/>
                           <br/>  The maximum recommended dose per 90 minute period of lidocaine hydrochloride for paracervical block in obstetrical patients and non-obstetrical patients is 200 mg total. One half of the total dose is usually administered to each side. Inject slowly, five minutes between sides (see also discussion of paracervical block in
 
  <content styleCode="bold">
                              <content styleCode="bold">
                                 <linkHtml href="#Section_6">PRECAUTIONS</linkHtml>
                              </content>
                           </content>). 
  <br/>
                           <br/>  For intravenous regional anesthesia, the dose administered should not exceed 4 mg/kg in adults.

 </paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="Unclassified_Section_17.2">
                     <id root="01ca2f07-9c54-e418-e063-6294a90ac760"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">
                           <content styleCode="italics">Children</content>
                        </content>
                     </title>
                     <text>
                        <br/>
                        <paragraph>It is difficult to recommend a maximum dose of any drug for children, since this varies as a function of age and weight. For children over 3 years of age who have a normal lean body mass and normal body development, the maximum dose is determined by the child’s age and weight. For example, in a child of 5 years weighing 50 lbs the dose of lidocaine hydrochloride should not exceed 75 to 100 mg (1.5 to 2 mg/lb). The use of even more dilute solutions (i.e., 0.25 to 0.5%) and total dosages not to exceed 3 mg/kg (1.4 mg/lb) are recommended for induction of intravenous regional anesthesia in children. 
  <br/>
                           <br/>  In order to guard against systemic toxicity, the lowest effective concentration and lowest effective dose should be used at all times. In some cases it will be necessary to dilute available concentrations with 0.9% sodium chloride injection in order to obtain the required final concentration. 
  <br/>
                           <br/>  NOTE: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever the solution and container permit. Do not use if solution is discolored or contains a precipitate.
 </paragraph>
                        <table cellspacing="0" cellpadding="0" border="0" width="722.19">
                           <caption>Table 1: Recommended Dosages</caption>
                           <col width="40.3314917127072%"/>
                           <col width="16.0220994475138%"/>
                           <col width="20.6261510128913%"/>
                           <col width="23.0202578268877%"/>
                           <thead>
                              <tr>
                                 <th rowspan="2" styleCode="Lrule Rrule Toprule">Procedure</th>
                                 <th colspan="3" align="center" styleCode="Lrule Rrule Toprule">Lidocaine Hydrochloride Injection 
     <br/>  (without epinephrine)
    </th>
                              </tr>
                              <tr>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Conc (%)</th>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Vol (mL)</th>
                                 <th align="center" styleCode="Lrule Rrule Toprule">Total Dose (mg)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="4">*Dose determined by number of dermatomes to be anesthetized (2 to 3 mL/dermatome). 
     <br/>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Infiltration 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Percutaneous 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.5 or 1 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1 to 60 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">5 to 300 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Intravenous regional 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">0.5 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">10 to 60 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">50 to 300 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Peripheral Nerve Blocks, e.g., 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Brachial 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.5 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">15 to 20 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">225 to 300 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Dental 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">2 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1 to 5 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">20 to 100 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Intercostal 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">3 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">30 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Paravertebral 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">3 to 5 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">30 to 50 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Pudendal (each side) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">10 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">100 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Paracervical 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Obstetrical analgesia (each side) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">10 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">100 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Sympathetic Nerve Blocks, e.g., 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Cervical (stellate ganglion) 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">5 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">50 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Lumbar 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">5 to 10 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">50 to 100 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Central Neural Blocks 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Epidural* 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Thoracic 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">20 to 30 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">200 to 300 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Lumbar 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Analgesia 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">25 to 30 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">250 to 300 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Anesthesia 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.5 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">15 to 20 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">225 to 300 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">2 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">10 to 15 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">200 to 300 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Caudal 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Obstetrical analgesia 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">20 to 30 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">200 to 300 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Surgical anesthesia 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">1.5 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">15 to 20 
     <br/>
                                 </td>
                                 <td align="center" styleCode="Rrule" valign="top">225 to 300 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>THE ABOVE SUGGESTED CONCENTRATIONS AND VOLUMES SERVE ONLY AS A GUIDE. OTHER VOLUMES AND CONCENTRATIONS MAY BE USED PROVIDED THE TOTAL MAXIMUM RECOMMENDED DOSE IS NOT EXCEEDED.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Unclassified_Section_20">
               <id root="01ca2f07-9c55-e418-e063-6294a90ac760"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>STERILIZATION, STORAGE AND TECHNICAL PROCEDURES</title>
               <text>
                  <br/>
                  <paragraph>Disinfecting agents containing heavy metals, which cause release of respective ions (mercury, zinc, copper, etc.) should not be used for skin or mucous membrane disinfection as they have been related to incidents of swelling and edema.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="01ccc502-893e-37e4-e063-6294a90a6ef7"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Lidocaine Hydrochloride Injection, USP is supplied as follows:
  <br/>
                     <br/>
Lidocaine Hydrochloride Injection USP, 1% (10 mg/mL)
  <br/>
                     <br/>
5 mL Single Dose Vials in a Carton of 10 NDC 55150-162-05
  <br/>
                     <br/>
                     <content styleCode="bold">Sterile, Nonpyrogenic</content>
                  </paragraph>
                  <paragraph>Discard unused portion
  <br/>
                     <br/>
                     <content styleCode="bold">Store at</content>20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
  <br/>
                     <br/>
The vial stopper is not made with natural rubber latex.
  <br/>
                     <br/>
Distributed by:
  <br/>
                     <content styleCode="bold">AuroMedics Pharma LLC</content>
                  </paragraph>
                  <paragraph>279 Princeton-Hightstown Rd.
  <br/>
E. Windsor, NJ 08520
  <br/>
                     <br/>
Manufactured by:
  <br/>
                     <content styleCode="bold">Aurobindo Pharma Limited</content>
                  </paragraph>
                  <paragraph>Hyderabad - 500038
  <br/>
India
 </paragraph>
                  <paragraph/>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Advanced Rx Pharmacy of Tennessee, LLC</content>
                     <br/>
                     <br/>
Revised: February 2020
 </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="La24a66a9-399c-433a-8c7f-1902be37a21c">
               <id root="01ca2f07-9c57-e418-e063-6294a90ac760"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>Povidone-Iodine Swabsticks</title>
               <text/>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="d62">
               <id root="01ca2f07-9c58-e418-e063-6294a90ac760"/>
               <code code="55106-9" codeSystem="2.16.840.1.113883.6.1" displayName="OTC - ACTIVE INGREDIENT SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Active Ingredient                                           Purpose</content>
                  </paragraph>
                  <paragraph>Povidone Iodine 10% w/v (9.85% w/w/)        Antiseptic</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section>
               <id root="01ca2f07-9c59-e418-e063-6294a90ac760"/>
               <code code="55105-1" codeSystem="2.16.840.1.113883.6.1" displayName="OTC - PURPOSE SECTION"/>
               <title>Purpose:</title>
               <text>
                  <paragraph>
                     <br/>  Purpose: 
  <br/>
                  </paragraph>
                  <list listType="unordered">
                     <item>First aid antiseptic to help prevent skin infection in minor cuts, scrapes and burns.</item>
                     <item>For preparation of the skin prior to surgery.</item>
                     <item>Helps reduce bacteria that can potentially cause skin infections.</item>
                  </list>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section>
               <id root="01ca2f07-9c5a-e418-e063-6294a90ac760"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>Warnings:</title>
               <text>
                  <list listType="unordered">
                     <item>
                        <content styleCode="bold">FOR EXTERNAL USE ONLY</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section>
               <id root="01ca2f07-9c5b-e418-e063-6294a90ac760"/>
               <code code="50570-1" codeSystem="2.16.840.1.113883.6.1" displayName="OTC - DO NOT USE SECTION"/>
               <title>Do not use:</title>
               <text>
                  <br/>
                  <list listType="unordered">
                     <item>As a first aid antiseptic for more than 1 week.</item>
                     <item>In the eyes.</item>
                     <item>Over large areas of the body. 
   <br/>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section>
               <id root="01ca2f07-9c5c-e418-e063-6294a90ac760"/>
               <code code="50569-3" codeSystem="2.16.840.1.113883.6.1" displayName="OTC - ASK DOCTOR SECTION"/>
               <title>Ask a doctor before use if you have:</title>
               <text>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <list listType="unordered">
                     <item>Deep puncture wounds</item>
                     <item>Animal bites</item>
                     <item>Serious burns 
   <br/>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section>
               <id root="01ca2f07-9c5d-e418-e063-6294a90ac760"/>
               <code code="50566-9" codeSystem="2.16.840.1.113883.6.1" displayName="OTC - STOP USE SECTION"/>
               <title>Stop Use:</title>
               <text>
                  <paragraph>
                     <br/>
                  </paragraph>
                  <list listType="unordered">
                     <item>If irritation and redness develop</item>
                     <item>If condition persists for more than 72 hours, consult a physician. 
   <br/>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section>
               <id root="01ca2f07-9c5e-e418-e063-6294a90ac760"/>
               <code code="50565-1" codeSystem="2.16.840.1.113883.6.1" displayName="OTC - KEEP OUT OF REACH OF CHILDREN SECTION"/>
               <title>Keep Out Of Reach Of Children</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Keep out of reach of children.</content>If swallowed, get medical help or contact a Poison Control Center. 
  <br/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section>
               <id root="01ca2f07-9c5f-e418-e063-6294a90ac760"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>Directions Povidone iodine:</title>
               <text>
                  <paragraph>Tear at notch, remove applicator, use only once.</paragraph>
                  <paragraph>
                     <content styleCode="bold">As a first aid antiseptic</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>clean affected area</item>
                     <item>apply 1 to 3 times daily</item>
                     <item>may be covered with a sterile bandage, if bandaged let dry.</item>
                  </list>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">For preoperative patient skin preparation 
   <br/>
                        <br/>
                     </content>
                  </paragraph>
                  <list listType="unordered">
                     <item>clean area</item>
                     <item>apply to operative site prior to surgery using the applicator 
   <br/>
                     </item>
                  </list>
                  <paragraph>
                     <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section>
               <id root="01ca2f07-9c60-e418-e063-6294a90ac760"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>Other information:</title>
               <text>
                  <paragraph>Store at room temperature.</paragraph>
                  <paragraph>Avoid excessive heat 
  <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section>
               <id root="01ca2f07-9c61-e418-e063-6294a90ac760"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <text>
                  <paragraph>For use as an 
  <br/>
                  </paragraph>
                  <list listType="unordered">
                     <item>first aid antiseptic 
   <br/>
                     </item>
                     <item>pre-operative skin preperation 
   <br/>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section>
               <id root="01ca2f07-9c62-e418-e063-6294a90ac760"/>
               <code code="51727-6" codeSystem="2.16.840.1.113883.6.1" displayName="INACTIVE INGREDIENT SECTION"/>
               <title>Inactive Ingredients</title>
               <text>
                  <paragraph>Inactive ingredients: Citric acid, glycerin, polysorbate 80, sodium citrate USP, sodium phosphate dibasic, water 
  <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="c88d89ed-094c-4517-8b04-6562ce524bbb">
               <id root="01ca2f07-9c63-e418-e063-6294a90ac760"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>0.9% Sodium Chloride Injection, USP</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Fliptop Plastic Vial</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">LifeShield
  
   <sup>®</sup>Fliptop Plastic Vial
 
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <content styleCode="bold">Preservative-Free</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="cc8773f5-5273-49c1-8b10-6b4ddcef9f98">
               <id root="01ca2f07-9c64-e418-e063-6294a90ac760"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>This preparation is designed solely for parenteral use only after addition of drugs that require dilution or must be dissolved in an aqueous vehicle prior to injection.</paragraph>
                  <paragraph>0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. 0.308 mOsmol/mL (calc.). 0.9% Sodium Chloride Injection, USP contains no preservatives. The solution may contain hydrochloric acid and/or sodium hydroxide for pH adjustment. pH 5.3 (4.5 to 7.0).</paragraph>
                  <paragraph>Sodium Chloride, USP is chemically designated NaCl, a white crystalline compound freely soluble in water.</paragraph>
                  <paragraph>The glass container is a Type I borosilicate glass and meets the requirements of the powdered glass test according to the USP standards.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="c9b73316-7cf4-4602-ae3b-e8b4931a7275">
               <id root="01ca2f07-9c65-e418-e063-6294a90ac760"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Sodium chloride in water dissociates to provide sodium (Na
 
  <sup>+</sup>) and chloride (Cl‾) ions. These ions are normal constituents of the body fluids (principally extracellular) and are essential for maintaining electrolyte balance.

 </paragraph>
                  <paragraph>The distribution and excretion of sodium (Na
 
  <sup>+</sup>) and chloride (Cl‾) are largely under the control of the kidney which maintains a balance between intake and output.

 </paragraph>
                  <paragraph>The small volume of fluid and amount of sodium chloride provided by 0.9% Sodium Chloride Injection, USP when used only as an isotonic vehicle for parenteral injection of drugs, is unlikely to exert a significant effect on fluid and electrolyte balance except possibly in neonates and very small infants.</paragraph>
                  <paragraph>Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).</paragraph>
                  <paragraph>Water balance is maintained by various regulatory mechanisms. Water distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na
 
  <sup>+</sup>) plays a major role in maintaining physiologic equilibrium.

 </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="a21ad6f9-17fe-4785-bca1-368243e2b74e">
               <id root="01ca2f07-9c66-e418-e063-6294a90ac760"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>This parenteral preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="efc61822-d7a1-49c5-a772-30b49c7fd146">
               <id root="01ca2f07-9c67-e418-e063-6294a90ac760"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <text>
                  <paragraph>Consult the manufacturer's instructions for choice of vehicle, appropriate dilution or volume for dissolving the drugs to be injected, including the route and rate of injection.</paragraph>
                  <paragraph>Inspect reconstituted (diluted or dissolved) drugs for clarity (if soluble) and freedom from unexpected precipitation or discoloration prior to administration.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Pregnancy:</content>Animal reproduction studies have not been conducted with 0.9% Sodium Chloride Injection, USP. It is also not known whether sodium chloride injection containing additives can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium chloride injection containing additives should be given to a pregnant woman only if clearly needed.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Pediatric Use:</content>The safety and effectiveness in the pediatric population are based on the similarity of the clinical conditions of the pediatric and adult populations. In neonates or very small infants the volume of fluid may affect fluid and electrolyte balance.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">Drug Interactions</content>
                  </paragraph>
                  <paragraph>Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.</paragraph>
                  <paragraph>Use aseptic technique for single or multiple entry and withdrawal from all containers.</paragraph>
                  <paragraph>When diluting or dissolving drugs, mix thoroughly and use promptly.</paragraph>
                  <paragraph>Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.</paragraph>
                  <paragraph>Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers, discard unused portion.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="e7851b18-363f-4559-96a0-c6555ceb12cc">
               <id root="01ca2f07-9c68-e418-e063-6294a90ac760"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Reactions which may occur because of this solution, added drugs or the technique of reconstitution or administration include febrile response, local tenderness, abscess, tissue necrosis or infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation.</paragraph>
                  <paragraph>If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate countermeasures, and if possible, retrieve and save the remainder of the unused vehicle for examination.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="c0116a76-52c6-4219-adf9-8db26644783d">
               <id root="01ca2f07-9c69-e418-e063-6294a90ac760"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Use only as a diluent or solvent. This parenteral preparation is unlikely to pose a threat of carbohydrate, sodium chloride or fluid overload except possibly in neonates or very small infants. In the event these should occur, re-evaluate the patient and institute appropriate corrective measures. See
 
  <content styleCode="bold">
                        <linkHtml href="#efc61822-d7a1-49c5-a772-30b49c7fd146">PRECAUTIONS</linkHtml>
                     </content>and
 
  <content styleCode="bold">
                        <linkHtml href="#e7851b18-363f-4559-96a0-c6555ceb12cc">ADVERSE REACTIONS</linkHtml>
                     </content>.

 </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="a1900ea0-b0c4-4125-8fab-dcd09dfc500b">
               <id root="01ca2f07-9c6a-e418-e063-6294a90ac760"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>The volume of the preparation to be used for diluting or dissolving any drug for injection, is dependent on the vehicle concentration, dose and route of administration as recommended by the manufacturer. This parenteral should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="d1a8862b-6fb4-46d8-a313-64e640feb3a8">
               <id root="01ccc780-2499-336a-e063-6294a90aa585"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>0.9% Sodium Chloride Injection, USP is supplied in the following:</paragraph>
                  <table width="90%">
                     <colgroup>
                        <col align="left" valign="top" width="65%"/>
                        <col align="left" valign="top" width="35%"/>
                     </colgroup>
                     <thead>
                        <tr styleCode="First Last">
                           <th align="left" styleCode="Rrule">Unit</th>
                           <th align="left">Concentration</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td align="left" styleCode="Rrule">
                              <content styleCode="bold">NDC 0409-4888-02</content>
                              <br/>
			10 mL Single-dose Plastic Fliptop Vials
    </td>
                           <td align="left">0.9% (10 mL)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Store at 20 to 25°C (68 to 77°F) [See USP Controlled Room Temperature.]</paragraph>
                  <paragraph>LIFESHIELD 
  <sup>®</sup>is the trademark of ICU Medical, Inc. and is used under license.
 </paragraph>
                  <paragraph>Distributed by Hospira, Inc., Lake Forest, IL 60045 USA </paragraph>
                  <paragraph>LAB-1097-2.0</paragraph>
                  <paragraph>10/2018</paragraph>
                  <paragraph/>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>Advanced Rx Pharmacy of Tennessee, LLC</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="b6326354-c82a-4c69-a432-5bc8066a3f83">
               <id root="01ca2f07-9c6c-e418-e063-6294a90ac760"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>Sterile Water for Injection, USP</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Plastic Vial</content>
                  </paragraph>
                  <paragraph>Rx only</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="e7b2efbd-ee42-401b-8c19-5aaab5f5cf3d">
               <id root="01ca2f07-9c6d-e418-e063-6294a90ac760"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>This preparation is designed solely for parenteral use only after addition of drugs that require dilution or must be dissolved in an aqueous vehicle prior to injection.</paragraph>
                  <paragraph>Sterile Water for Injection, USP is a sterile, nonpyrogenic preparation of water for injection which contains no bacteriostat, antimicrobial agent or added buffer and is supplied only in single-dose containers to dilute or dissolve drugs for injection. For I.V. injection, add sufficient solute to make an approximately isotonic solution.</paragraph>
                  <paragraph>Water for Injection, USP is chemically designated H
 
  <sub>2</sub>O.

 </paragraph>
                  <paragraph>The semi-rigid vial is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers. The container requires no vapor barrier to maintain the proper labeled volume.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="b149c01f-4888-4df6-9f78-6ac7a30e6149">
               <id root="01ca2f07-9c6e-e418-e063-6294a90ac760"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>Water is an essential constituent of all body tissues and accounts for approximately 70% of total body weight. Average normal adult daily requirement ranges from two to three liters (1.0 to 1.5 liters each for insensible water loss by perspiration and urine production).</paragraph>
                  <paragraph>Water balance is maintained by various regulatory mechanisms. Water for distribution depends primarily on the concentration of electrolytes in the body compartments and sodium (Na
 
  <sup>+</sup>) plays a major role in maintaining physiologic equilibrium.

 </paragraph>
                  <paragraph>The small volume of fluid provided by Sterile Water for Injection, USP when used only as a pharmaceutic aid for diluting or dissolving drugs for parenteral injection, is unlikely to exert a significant effect on fluid balance except possibly in neonates or very small infants.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="c11cb0fe-fa17-4a4c-959c-a4ddf47653bd">
               <id root="01ca2f07-9c6f-e418-e063-6294a90ac760"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>This parenteral preparation is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="aee6d6cb-cc98-4d29-9901-f56da450d50b">
               <id root="01ca2f07-9c70-e418-e063-6294a90ac760"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Sterile Water for Injection, USP must be made approximately isotonic prior to use.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="c0be72b6-25ee-49c0-8397-8749e9f8afaa">
               <id root="01ca2f07-9c71-e418-e063-6294a90ac760"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>Intravenous administration of Sterile Water for Injection without a solute may result in hemolysis.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="adc10c02-8ba0-46dd-8cf8-4c0ed9da196b">
               <id root="01ca2f07-9c72-e418-e063-6294a90ac760"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <text>
                  <paragraph>Do not use for intravenous injection unless the osmolar concentration of additives results in an approximate isotonic admixture.</paragraph>
                  <paragraph>Consult the manufacturer's instructions for choice of vehicle, appropriate dilution or volume for dissolving the drugs to be injected, including the route and rate of injection.</paragraph>
                  <paragraph>Inspect reconstituted (diluted or dissolved) drugs for clarity (if soluble) and freedom from unexpected precipitation or discoloration prior to administration.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Pregnancy:</content>Animal reproduction studies have not been conducted with Sterile Water for Injection. It is also not known whether sterile water containing additives can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sterile Water for Injection with additives should be given to a pregnant woman only if clearly needed.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Pediatric Use</content>
                     </content>
                  </paragraph>
                  <paragraph>Safety and effectiveness have been established in pediatric patients. However, in neonates or very small infants the volume of fluid may affect fluid and electrolyte balance.</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="italics">Drug Interactions</content>
                     </content>
                  </paragraph>
                  <paragraph>Some drugs for injection may be incompatible in a given vehicle, or when combined in the same vehicle or in a vehicle containing benzyl alcohol. Consult with pharmacist, if available.</paragraph>
                  <paragraph>Use aseptic technique for single or multiple entry and withdrawal from all containers.</paragraph>
                  <paragraph>When diluting or dissolving drugs, mix thoroughly and use promptly.</paragraph>
                  <paragraph>Do not store reconstituted solutions of drugs for injection unless otherwise directed by the manufacturer of the solute.</paragraph>
                  <paragraph>Do not use unless the solution is clear and seal intact. Do not reuse single-dose containers. Discard unused portion.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="cbeb4367-3ce6-4af4-9b43-51018789ce73">
               <id root="01ca2f07-9c73-e418-e063-6294a90ac760"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Reactions which may occur because of this solution, added drugs or the technique of reconstitution or administration include febrile response, local tenderness, abscess, tissue necrosis or infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection and extravasation.</paragraph>
                  <paragraph>If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate countermeasures, and if possible, retrieve and save the remainder of the unused vehicle for examination.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="cc332673-9b6a-4a2a-8de0-0b2db2a0994b">
               <id root="01ca2f07-9c74-e418-e063-6294a90ac760"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Use only as a diluent or solvent. This parenteral preparation is unlikely to pose a threat of fluid overload except possibly in neonates or very small infants. In the event these should occur, re-evaluate the patient and institute appropriate corrective measures. See
 
  <content styleCode="bold">
                        <linkHtml href="#c0be72b6-25ee-49c0-8397-8749e9f8afaa">WARNINGS</linkHtml>
                     </content>,
 
  <content styleCode="bold">
                        <linkHtml href="#adc10c02-8ba0-46dd-8cf8-4c0ed9da196b">PRECAUTIONS</linkHtml>
                     </content>and
 
  <content styleCode="bold">
                        <linkHtml href="#cbeb4367-3ce6-4af4-9b43-51018789ce73">ADVERSE REACTIONS</linkHtml>
                     </content>.

 </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="dc0b6ed1-3879-49c6-9c73-a394f48f2bcf">
               <id root="01ca2f07-9c75-e418-e063-6294a90ac760"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>The volume of the preparation to be used for diluting or dissolving any drug for injection is dependent on the vehicle concentration, dose and route of administration as recommended by the manufacturer.</paragraph>
                  <paragraph>This parenteral should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="d8a9f149-0a20-4b24-88cb-cdd73c9aa59d">
               <id root="01ccc780-249b-336a-e063-6294a90aa585"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Sterile Water for Injection, USP is supplied in the following:</paragraph>
                  <table width="100%">
                     <colgroup>
                        <col align="center" valign="middle" width="50%"/>
                        <col align="center" valign="middle" width="50%"/>
                     </colgroup>
                     <thead>
                        <tr styleCode="First Last">
                           <th align="center" styleCode="Lrule Rrule">Unit</th>
                           <th align="center" styleCode="Lrule Rrule">Total Content</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule First Last">
                           <td align="center" styleCode="Lrule Rrule">
                              <content styleCode="bold">NDC 0409-4887-17</content>
                              <br/>
			1 Plastic Fliptop Vials
    </td>
                           <td align="center" styleCode="Lrule Rrule">10 mL</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]</paragraph>
                  <paragraph>Distributed by Hospira, Inc., Lake Forest, IL 60045 USA</paragraph>
                  <paragraph>LAB-1292-1.0</paragraph>
                  <paragraph>Revised: 05/2018</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Advanced Rx Pharmacy of Tennessee, LLC</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="L6f116f79-2120-4434-887b-1f2d3d836db0">
               <id root="01ca2f07-9c77-e418-e063-6294a90ac760"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>Isopropyl Alcohol 70% Prep Pads</title>
               <text/>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="i4i_OTC_Active_Ingredient_id_bd991a0b-fdf3-4210-a559-8be5d74f69ab">
               <id root="01ca2f07-9c78-e418-e063-6294a90ac760"/>
               <code code="55106-9" codeSystem="2.16.840.1.113883.6.1" displayName="OTC - ACTIVE INGREDIENT SECTION"/>
               <title>Active ingredient</title>
               <text>
                  <paragraph>Isopropyl Alcohol 70% v/v 
  <br/>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="i4i_OTC_Purpose_id_68967d10-7557-4f16-bcc9-fead4b911c53">
               <id root="01ca2f07-9c79-e418-e063-6294a90ac760"/>
               <code code="55105-1" codeSystem="2.16.840.1.113883.6.1" displayName="OTC - PURPOSE SECTION"/>
               <title>Purpose</title>
               <text>
                  <paragraph>Antiseptic</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="i4i_indications_id_458d385e-40b4-4f69-b21f-8be762572a3b">
               <id root="01ca2f07-9c7a-e418-e063-6294a90ac760"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>Uses</title>
               <text>
                  <paragraph>For first aid to decrease germs in</paragraph>
                  <list listType="unordered">
                     <item>minor cuts</item>
                     <item>scrapes</item>
                     <item>burns</item>
                  </list>
                  <paragraph>For preparation of the skin prior to injection</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="i4i_warnings_id_d71ed11d-8921-42bd-b11a-7ecba9eb61c7">
               <id root="01ca2f07-9c7b-e418-e063-6294a90ac760"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>Warnings</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">For external use only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Flammable - keep away from fire or flame</content>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
               <component>
                  <section ID="i4i_OTC_Do_not_use_id_fb5ddee8-0adf-4658-9553-9c7725cc8aee">
                     <id root="01ca2f07-9c7c-e418-e063-6294a90ac760"/>
                     <code code="50570-1" codeSystem="2.16.840.1.113883.6.1" displayName="OTC - DO NOT USE SECTION"/>
                     <title>Do not use</title>
                     <text>
                        <paragraph>with electrocautery procedures</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_OTC_When_Using_id_79f29cbb-ac17-40b5-ab3d-77cd2845b305">
                     <id root="01ca2f07-9c7d-e418-e063-6294a90ac760"/>
                     <code code="50567-7" codeSystem="2.16.840.1.113883.6.1" displayName="OTC - WHEN USING SECTION"/>
                     <title>When using this product do not</title>
                     <text>
                        <list listType="unordered">
                           <item>get into eyes</item>
                           <item>apply over large areas of the body</item>
                           <item>in case of deep or puncture wounds, animal bites or serious burns consult a doctor</item>
                        </list>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_OTC_Stop_Use_id_14379cb0-702b-43b5-8d7a-d81337b231c3">
                     <id root="01ca2f07-9c7e-e418-e063-6294a90ac760"/>
                     <code code="50566-9" codeSystem="2.16.840.1.113883.6.1" displayName="OTC - STOP USE SECTION"/>
                     <title>Stop use and ask a doctor if</title>
                     <text>
                        <list listType="unordered">
                           <item>condition persists or gets worse or lasts for more than 72 hours</item>
                           <item>do not use longer than 1 week unless directed by a doctor</item>
                        </list>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
               <component>
                  <section ID="i4i_OTC_Keep_Away_Children_id_6281159d-6496-4372-b97b-c20af304baa6">
                     <id root="01ca2f07-9c7f-e418-e063-6294a90ac760"/>
                     <code code="50565-1" codeSystem="2.16.840.1.113883.6.1" displayName="OTC - KEEP OUT OF REACH OF CHILDREN SECTION"/>
                     <title>Keep out of reach of children.</title>
                     <text>
                        <paragraph>If swallowed, get medical help or contact a Poison Control Center right away.</paragraph>
                     </text>
                     <effectiveTime value="20230731"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="i4i_dosage_admin_id_5750d15e-683a-4572-b2e8-bff0a2eb29d6">
               <id root="01ca2f07-9c80-e418-e063-6294a90ac760"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>Directions</title>
               <text>
                  <list listType="unordered">
                     <item>apply to skin as needed</item>
                     <item>discard after single use</item>
                  </list>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="i4i_storage_id_a11fdb34-d958-4e44-82c8-197270227b99">
               <id root="01ca2f07-9c81-e418-e063-6294a90ac760"/>
               <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
               <title>Other information</title>
               <text>
                  <paragraph>Protect from freezing and avoid excessive heat</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="i4i_inactive_ingredients_id_3ef9a0db-3a14-4a6e-9183-6b8d44953eaf">
               <id root="01ca2f07-9c82-e418-e063-6294a90ac760"/>
               <code code="51727-6" codeSystem="2.16.840.1.113883.6.1" displayName="INACTIVE INGREDIENT SECTION"/>
               <title>Inactive ingredient</title>
               <text>
                  <paragraph>Water</paragraph>
               </text>
               <effectiveTime value="20230731"/>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="01ccd14b-1bb5-a616-e063-6394a90aa42f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC: 80425-0349-01</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Dyural-80</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Kit Contains</content>
                  </paragraph>
                  <paragraph>1 MethylPREDNISolone Acetate Injec table Suspension, USP 80mg/mL Single Dose Vial (1mL)</paragraph>
                  <paragraph>1 Bupivacaine HCl 0.25% Single Dose Vial (10mL)</paragraph>
                  <paragraph>1 Lidocaine HCl Injection, USP 1% Single Dose Vial (5mL)</paragraph>
                  <paragraph>1 Sterile Water for Inj., USP (10mL)</paragraph>
                  <paragraph>1 0.9% Sodium Chloride Inj., USP (10mL)</paragraph>
                  <paragraph>1 Povidone-Iodine Swabsticks (3 Swabs)</paragraph>
                  <paragraph>5 Isopropyl Alcohol 70% Prep Pads</paragraph>
                  <paragraph>1 Pair Nitrile Powder Free Sterile Gloves (M)</paragraph>
                  <paragraph>1 Drape with Fenestration</paragraph>
                  <paragraph>1 Adhesive Bandage</paragraph>
                  <paragraph>5 Non Sterile 4x4 Gauze</paragraph>
                  <paragraph>Needles and Syringes Not Included</paragraph>
                  <paragraph>1 Dose</paragraph>
                  <paragraph>Single Use Only</paragraph>
                  <paragraph>Distributed by:</paragraph>
                  <paragraph>Advanced Rx Pharmacy of Tennessee, LLC</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_01ccc780-249c-336a-e063-6294a90aa585"/>
                  </paragraph>
               </text>
               <effectiveTime value="20230731"/>
               <component>
                  <observationMedia ID="img_01ccc780-249c-336a-e063-6294a90aa585">
                     <text>label 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Dyural 80 Kit 80425-0349-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>